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A critical determinant in chronic gammaherpesvirus infections is the ability of these viruses to establish latency in a
lymphocyte reservoir. The nuclear factor (NF)-jB family of transcription factors represent key players in B-cell biology
and are targeted by gammaherpesviruses to promote host cell survival, proliferation, and transformation. However,
the role of NF-jB signaling in the establishment of latency in vivo has not been addressed. Here we report the
generation and in vivo characterization of a recombinant murine gammaherpesvirus 68 (cHV68) that expresses a
constitutively active form of the NF-jB inhibitor, IjBaM. Inhibition of NF-jB signaling upon infection with cHV68-IjBaM
did not affect lytic replication in cell culture or in the lung following intranasal inoculation. However, there was a
substantial decrease in the frequency of latently infected lymphocytes in the lung (90% reduction) and spleens (97%
reduction) 16 d post intranasal inoculation. Importantly, the defect in establishment of latency in lung B cells could not
be overcome by increasing the dose of virus 100-fold. The observed decrease in establishment of viral latency
correlated with a loss of activated, CD69
hi B cells in both the lungs and spleen at day 16 postinfection, which was not
apparent by 6 wk postinfection. Constitutive expression of Bcl-2 in B cells did not rescue the defect in the
establishment of latency observed with cHV68-IjBaM, indicating that NF-jB–mediated functions apart from Bcl-2–
mediated B-cell survival are critical for the efficient establishment of gammaherpesvirus latency in vivo. In contrast to
the results obtained following intranasal inoculation, infection of mice with cHV68-IjBaM by the intraperitoneal route
had only a modest impact on splenic latency, suggesting that route of inoculation may alter requirements for
establishment of virus latency in B cells. Finally, analyses of the pathogenesis of cHV68-IjBaM provides evidence that
NF-jB signaling plays an important role during multiple stages of cHV68 infection in vivo and, as such, represents a
key host regulatory pathway that is likely manipulated by the virus to establish latency in B cells.
Citation: Krug LT, Moser JM, Dickerson SM, Speck SH (2007) Inhibition of NF-jB activation in vivo impairs establishment of gammaherpesvirus latency. PLoS Pathog 3(1): e11.
doi:10.1371/journal.ppat.0030011
Introduction
Murine gammaherpesvirus 68 (cHV68) shares many genetic
and biologic properties with its human counterparts, Epstein-
Barr virus (EBV) and Kaposi sarcoma–associated herpesvirus
(KSHV or HHV-8). For example, it has been shown for both
EBV and cHV68 that long-term latency is maintained in
memory B cells [1–3]. Identifying the host-dependent require-
ments for gaining access to the latency reservoir is an
important step toward understanding how the virus modu-
lates the host to establish a chronic infection. Such virus–host
interactions may lead to dysregulation of normal cellular
controls, increasing the risk for the development of lympho-
mas and other tumors etiologically associated with gamma-
herpesvirus infections [4,5].
Nuclear factor (NF)-jB transcription factors are key regu-
latory molecules of genes involved in innate and adaptive
immunity. The absence of particular NF-jB subunits, or
upstream regulatory molecules, can result in defects in B-cell
development and functions such as activation-induced pro-
liferation (reviewed in [6–8]). The maturation of B cells and
survival in the periphery involve NF-jB–mediated upregula-
tion of antiapoptotic bcl-2, bcl-xL, and bﬂ-1/A1 genes [7,9]. The
proliferative response of B cells to stimulation requires NF-jB–
mediated upregulation of c-Myc, cyclins, and CDK4 [7,10,11].
The NF-jB family of transcription factors is comprised of
the subunits p65 (RelA), cRel, RelB, p50 (NF-jB1), and p52
(NF-jB2) that form dimers to mediate sequence-speciﬁc
regulation of gene expression upon activation. Dimers of NF-
jB subunits are retained in the cytoplasm by inhibitory IjB
molecules. Cellular activation leads to proteosomal-depend-
ent degradation of IjB molecules and translocation of NF-jB
dimers to the nucleus. The engagement of cell surface
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matory cytokines (e.g., tumor necrosis factor [TNF] a), and
Toll-like receptors lead to the release of p50:cRel and
p50:relA dimers through the classic pathway. The phosphor-
ylation and subsequent degradation of the inhibitor of NF-
jB, IjBa, are mediated by the IjB kinase (IKK) complex
(IKK1, IKK2, and NEMO). In contrast, engagement of
receptors such as the lymphotoxin b receptor and the B-
cell–activating factor of the TNF family (BAFF) leads to the
release of p52:RelB dimers via the alternative IKK1/NIK-
dependent pathway (reviewed in [12]). Engagement of
primary B cells with CD40L leads to the activation of NF-
jB via both the classic and alternative pathways [11].
Given the critical role that NF-jB plays in B-cell biology,
lymphotropic gammaherpesviruses have evolved multiple
strategies to modulate NF-jB activity in infected cells. For
example, the latent membrane protein 1 (LMP-1) encoded by
EBV is expressed during the growth latency program and is
essential for EBV immortalization of primary B cells [13,14].
LMP-1 drives NF-jB activation and is able to partially restore
CD40-dependent functions in transgenic mice, indicating
that it functions as a constitutively active CD40 receptor [15–
17]. In the case of KSHV latency, the virus-encoded vFLIP has
been shown to be essential for the proliferation and survival
of primary effusion lymphoma cells, driving NF-jB activation
via interactions with the TNF receptor–associated factors
TRAF2 and TRAF3 [18–20]. Thus, it is likely that manipu-
lation of NF-jB signaling is critical for the establishment and
maintenance of gammaherpesvirus latency in vivo; however,
to date this remains untested.
cHV68 infection of mice represents a tractable animal
model in which both viral and host factors that modulate
acute replication, latency, and reactivation can be addressed.
Intranasal infection with cHV68 results in acute virus
replication in the lungs, followed by B-cell–dependent spread
of virus to the spleen, in turn followed by acute replication
and establishment of latency in the spleen [21–25]. Subse-
quent to immune clearance of acute virus replication,
multiple cell types, including lung epithelial cells, B cells,
dendritic cells, and macrophages, are found to harbor the
viral genome in the absence of preformed infectious virus
[23,26–29]. Splenic B cells infected with cHV68 undergo
proliferation and bear surface markers of cells that partic-
ipate in germinal centers, sites of afﬁnity maturation, and
differentiation into long-lived memory B cells and antibody-
producing plasma cells [2,27,30–32]. Notably, isotype-class–
switched memory B cells are the predominant reservoir for
latent cHV68 infection at late timepoints postinfection [2,3].
Thus, cHV68 pathogenesis has strong parallels with EBV
infection in humans, where EBV latency is characterized by
distinct latency programs involving differential expression of
speciﬁc viral genes that modulate host signaling pathways to
facilitate the proliferation of naı ¨ve cells into lymphoblasts,
followed by differentiation of these lymphoblasts into
memory B cells [13]. As with KSHV, cHV68 lacks clear
homologs of the EBV latency-associated antigens, yet it has
likely evolved a strategy for promoting the activation,
proliferation, and differentiation of newly infected B cells
into the memory B-cell reservoir.
NF-jB likely plays a critical role in multiple aspects of
cHV68 pathogenesis. The role of one upstream activator of
NF-jB, CD40, has been examined in the context of an intact
immune response. Blackman et al. [3] infected CD40
þ/CD40
 
mixed bone marrow chimeric mice and reported that CD40-
deﬁcient B cells latently infected with cHV68 rapidly waned
compared to latency in CD40-sufﬁcient B cells. This suggests
that NF-jB activation upon CD40L stimulation plays a role in
the maintenance of latency in B cells [3]. Finally, replication
of cHV68 in cell culture is blocked by overexpression of p65,
and it has been proposed that NF-jB activation may promote
the establishment of latency by inhibiting lytic cycle initiation
[33].
Here we sought to address the role of NF-jB signaling in
vivo using virus-directed inhibition of NF-jB activation. This
experimental approach avoids the global immune dysfunc-
tion present in NF-jB knockout mice, which would not allow
the role of NF-jB activation in the establishment of viral
latency in B cells to be readily distinguished from its role in
the immune response and subsequent control of cHV68
infection. To this end, we report the generation and
characterization of a recombinant cHV68 expressing a
mutant form of the NF-jB inhibitor IjBa,I jBaM, that
functions as a superrepressor of NF-jB activation. We ﬁnd
that while dispensable for in vitro replication, NF-jB
activation is a critical host determinant for cHV68 latency
in vivo.
Results
Targeted Disruption of NF-jB Signaling in
cHV68-Infected Cells
To investigate the consequences of inhibiting the NF-jB
signaling pathway during the infection of mice with cHV68,
yet avoid global alterations in the immune response, we
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Author Summary
A central aspect of chronic infection of a host by herpesviruses is the
ability of these viruses to establish a quiescent infection (latent
infection) in some cell type(s) in which there is only intermittent
production of progeny virus (virus reactivation). The establishment
of a latent infection in the antibody producing cells of the host
immune system (B lymphocytes) is critical for life-long persistence of
gammaherpesviruses, as well as the development of virus-associ-
ated lymphoproliferative diseases (e.g., B-cell lymphomas). Nuclear
factor (NF)-jB transcription factors are a family of cellular proteins
that play an important role regulating gene expression in B cells,
and it has been shown that gammaherpesviruses have evolved
multiple strategies for manipulating NF-jB activity. However, to date
there has been no reported examination of the role of NF-jB in the
establishment of chronic gammaherpesvirus infection in vivo.
Murine gammaherpesvirus 68 (cHV68) infects rodents and shares
genetic and biologic properties with the human gammaherpesvi-
ruses, Epstein-Barr virus and Kaposi sarcoma–associated herpesvirus.
To selectively block the function of NF-jB in infected cells, we
engineered a transgenic virus that expresses a repressor of NF-jB
activation (IjBaM). Notably, this recombinant virus was defective in
the establishment of latency in B cells in the lungs and spleen
following intranasal inoculation. We also observed that the decrease
in B-cell infection could not be rescued by forced expression of the
cellular Bcl-2 protein, which is normally upregulated by NF-jB and
serves to protect B cells from some forms of cell death. Thus, we
conclude that NF-jB is an important host factor for the successful
establishment of a chronic infection by gammaherpesviruses, and
likely requires functions of NF-jB apart from its role in B-cell survival.generated a recombinant cHV68 that would inhibit NF-jB
signaling only in infected cells. To accomplish this, we used a
mutant form of IjBa,I jBaM, that contains serine-to-alanine
substitutions at amino acids 32 and 36, thus preventing
phosphorylation, proteasomal degradation, and release of
NF-jB dimers to the nucleus following appropriate upstream
stimuli [34]. This ‘‘superrepressor’’ functions as a potent
transdominant inhibitor of NF-jB activation in cell culture
[35–37] and in vivo [38]. We inserted an IjBaM expression
cassette, driven by the HCMV major immediate-early
promoter (MIEP), into the intergenic region between ORFs
27 and 29b of cHV68 (Figure 1A). It has previously been
shown that insertion of a HCMV MIEP-driven Cre recombi-
nase expression cassette [32], insertion of a transposon [39] or
the mutagenesis of ORF28 in this region [40] does not impair
virus replication in vitro [39,40] or in vivo [40], and has no
discernable impact on the establishment of, or reactivation
from, splenic latency in C57BL/6 mice [32,40].
The IjBaM.1 and IjBaM.2 recombinant viruses were
generated as described in Materials and Methods through
allelic exchange in Escherichia coli utilizing a cHV68-BAC [41]
followed by removal of BAC sequences through Cre-mediated
recombination in Vero-Cre cells. We generated two inde-
pendent recombinant cHV68 viruses, IjBaM.1 and IjBaM.2,
which contain the IjBaM expression cassette in either the
rightward or leftward orientation within the viral genome,
respectively (Figure 1A). In addition, two independent
marker rescue viruses were generated through allelic ex-
change with IjBaM.1, one of which (IjBaM.MR) was fully
characterized here. As shown in Figure 1B, Southern analysis
of BamHI-digested viral DNA isolated from extracellular
virions, followed by hybridization with a [
32P]-labeled probe
speciﬁc for IjBaM, detected the IjBaM insert only in the
IjBaM.1 and IjBaM.2 recombinant viruses (revealing the
expected product sizes of 5,477 bp and 5,127 bp, respectively).
A probe containing a portion of ORF27 and the ORF27-29b
intergenic region identiﬁed the expected 4,416-bp fragment
in HindIII-digested wild-type (WT) and IjBaM.MR viral
DNAs. As expected, the introduction of a new HindIII site
within the IjBaM insert resulted in a reduction in the sizes of
the hybridizing fragments for the recombinant viruses
harboring the IjBaM expression cassette in the rightward
(IjBaM.1; 1,682 bp) or leftward (IjBaM.2; 2,321 bp) orienta-
tion (Figure 1B).
The ability of the IjBaM-expressing viruses to inhibit NF-
jB activation in the context of virus infection was examined
using an NF-jB–responsive reporter construct in infected
cells. NIH 3T12 ﬁbroblasts were infected with WT cHV68 at a
multiplicity of infection (MOI) of 1 or 10 for 6 h followed by
transfection with an NF-jB–dependent luciferase construct,
in the presence or absence of an expression construct for
MEKK1. At 24 hours postinfection (hpi), cells were harvested
and luciferase activity was quantitated. Notably, infection
with WT cHV68 activated the NF-jB–dependent reporter
construct in a dose-dependent manner to levels nearly 8-fold
over uninfected samples (Figure 2A). This activation syner-
gized with MEKK1 activation to further enhance NF-jB
activation of the reporter construct over 100-fold compared
to mock infected samples (Figure 2A). In an independent
experiment, the synergistic induction of the NF-jB–respon-
sive reporter construct by MEKK1 and cHV68 infection was
used to examine the recombinant IjBaM-expressing viruses.
Consistent with the results shown in Figure 2A, infection of
WT or IjBaM.MR virus enhanced MEKK1 activation of the
NF-jB–responsive reporter construct approximately 10-fold
above that observed in mock infected cells (Figure 2B). In
Figure 1. Construction and Verification of the cHV68-IjBaM Viruses
(A) Genomic structure of WT cHV68, cHV68-IjBaM.1 and cHV68-IjBaM.2,
and cHV68-IjBaM.MR in the ORF27-29b intergenic region. In cHV68-
IjBaM.1 and .2 viruses, the 1.8-kb HCMV immediate-early promoter-
driven IjBaM expression cassette was inserted at the PmlI site in either
the rightward or leftward orientation, respectively. All genome
coordinates are based on the cHV68 WUMS sequence. Bars below the
genomic regions indicate regions used as probes in the Southern blot. B,
BamHI; H, HindIII; P, PmlI.
(B) Southern blot analysis of WT cHV68, cHV68-IjBaM.1 and cHV68-
IjBaM.2, and cHV68-IjBaM.MR viral genomes. Viral DNA was purified
from extracellular virions and subsequently digested with BamHI or
HindIII, electrophoresed, blotted, and hybridized with a
32P-labeled
probe as indicated. The fragment sizes of
32P-labeled BstEII-digested
Lambda DNA are indicated.
doi:10.1371/journal.ppat.0030011.g001
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MEKK1 activation of the NF-jB–responsive reporter con-
struct (Figure 2B). Analysis of NF-jB activity in cells infected
with a recombinant cHV68 harboring a CMV MIEP-driven
CRE-recombinase expression cassette in the intragenic
region between ORFs 27 and 29b revealed no inhibition of
NF-jB activation, arguing against interference with NF-jB
activation due to insertion of the CMV MIEP-driven
expression cassette in this region of the viral genome
(unpublished data). Taken together, these data directly
demonstrate effective inhibition of NF-jB activation by the
recombinant viruses expressing IjBaM, in response to both
virus infection and MEKK1-driven activation.
To further examine activation of NF-jB upon cHV68
infection of murine ﬁbroblasts, nuclear extracts were
prepared from mock infected NIH 3T12 cells, as well as from
NIH 3T12 cells infected with either WT cHV68, IjBaM.1, or
IjBaM.MR. Electrophoretic mobility shift analysis of nuclear
extracts incubated with a consensus NF-jB binding site
revealed the induction of NF-jB binding activity in WT and
IjBaM.MR virus–infected cells but not in the IjBaM.1-
infected cells (Figure 2C). Furthermore, the induced NF-jB
complex could be competed by an unlabeled double-stranded
oligonucleotide probe containing a consensus NF-jB binding
site but not by a competitor containing a mutated NF-jB
binding site (Figure 2C). Electrophoretic mobility supershift
analyses of the induced NF-jB complex, using antibodies
targeted against speciﬁc NF-jB family members, demonstra-
ted that the induced complex contains p65 but does not
appear to contain either c-rel or p50 (unpublished data).
NF-jB Activation Is Dispensable for Virus Replication in
Tissue Culture or In Vivo in the Lung
The ability to easily generate high-titer viral stocks from
the initial transfection of cHV68-IjBaM BAC DNA into
Vero-Cre cells indicated that insertion of the IjBaM
expression cassette into the viral genome does not appreci-
ably impair viral replication in vitro. To quantitatively assess
the role of NF-jB signaling during lytic replication, we
compared replication of IjBaM.1 and IjBaM.MR in primary
mouse embryonic ﬁbroblasts (MEFs). MEFs were infected for
single-step (MOI ¼ 5.0) and multistep (MOI ¼ 0.05) growth
assays, followed by analysis of virus growth at various times
postinfection by plaque assay on NIH 3T12 cells. Notably, the
kinetics of virus replication in the single-step (Figure 3A) and
multistep (Figure 3B) growth curves were nearly indistin-
guishable between IjBaM.1 and IjBaM.MR viruses. The
replication of IjBaM.1, and IjBaM.2, IjBaM.MR, and WT
cHV68 in NIH 3T12s was also compared in a multistep
growth analysis (Figure 3C). Consistent with the analyses
shown in Figure 3A, all viruses replicated with similar kinetics
and to comparable virus titers across the 96-h time course
Figure 2. cHV68-IjBaM Inhibits NF-jB Signaling in Fibroblasts
(A) NIH 3T12 fibroblasts were infected with WT virus at an MOI of 1 or 10
for 6 h and then transfected with a NF-jB–responsive luciferase reporter
construct and, where indicated, a plasmid expressing MEKK1. Data are
shown as the mean fold activation of the NF-jB promoter over mock
infected samples 6SD of triplicate wells.
(B) NIH 3T12 cells were infected with the indicated viruses at an MOI of
10 for 6 h and then transfected with the NF-jB luciferase reporter
construct and a plasmid expressing MEKK1. At 24 h posttransfection,
wells were harvested and luciferase activity was quantitated. Data are
shown as the mean fold activation of the NF-jB promoter over mock
infected, MEKK1-transfected samples 6SD of triplicate wells and are
representative of multiple independent experiments. IjBaM.R1 and
IjBaM.R2 were viruses recovered from reactivating splenocytes har-
vested from mice infected with either the IjBaM.1 or IjBaM.2
recombinant virus, respectively.
(C) Electrophoretic mobility shift analysis of NF-jB binding using nuclear
extracts prepared from NIH 3T12 cells infected with the indicated viruses
at an MOI of 3 for 48 h, as described in Materials and Methods. Also
shown, as a positive control for NF-jB induction, is treatment of
uninfected NIH 3T12 cells with 25 ng/ml TNFa for 1 h prior to harvest.
Specific (arrow) and nonspecific (open circle) complexes are indicated.
doi:10.1371/journal.ppat.0030011.g002
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IjBaM expression construct into the viral genome (in the
intragenic region between ORFs 27 and 29b), and the
resulting inhibition of NF-jB signaling by IjBaM expression,
did not negatively impact cHV68 replication in vitro.
Upon intranasal infection of mice, cHV68 undergoes a lytic
replicative expansion in the lung epithelium prior to
trafﬁcking and seeding of other target organs and tissues,
such as the spleen. The ability of the recombinant viruses
expressing IjBaM to replicate in the lungs of C57BL/6 (BL6)
mice during this acute phase was examined (Figure 3D). At
days 4 and 9, following intranasal inoculation with 1,000 PFU
of virus, lungs were harvested, disrupted and virus titers
determined. Acute viral titers in mice infected with the
IjBaM.1 and IjBaM.2 recombinant viruses were comparable
to that observed in mice infected with either WT virus or
IjBaM.MR (Figure 3D). Thus, we conclude that NF-jB
activation is dispensable for productive replication in the
lungs during the acute phase of virus infection. Interestingly,
productive replication of the IjBaM-expressing virus follow-
ing low-dose intranasal inoculation was slightly impaired
when compared to IjBaM.MR, although replication of both
the IjBaM.MR- and the IjBaM-expressing virus in the spleen
was very low (or not detectable) at all times postinfection
(Figure 3E). We have previously reported that low-dose
intranasal inoculation (40 PFU) leads to delayed seeding
and clearance of acute virus replication in the lungs and the
spleen compared to high-dose inoculation (4310
5 PFU) [25].
However, IjBaM.1 was observed to replicate with normal
replication kinetics in the lung (Figure 3D), and the low level
of lytic replication of IjBaM.1 in the spleen provided no
evidence for delayed clearance of acute replication upon
infection with IjBaM.1. As discussed below, a defect in acute
IjBaM.1 replication in the spleen was also noted at day 9 post
Figure 3. Inhibition of NF-jB Signaling Does Not Impair Lytic Replication In Vitro or Acute Replication in the Lungs
(A) Single-step growth curve in MEFs, with an MOI of 5.0 PFU per cell with the indicated virus. Samples were harvested at the indicated time points and
titers were determined on NIH 3T12 fibroblasts as described in Materials and Methods.
(B) Multistep growth curve in MEFs, with an MOI of 0.05 PFU per cell with the indicated viruses.
(C) Multistep growth curve in NIH 3T12 cells, with an MOI of 0.05 PFU per cell with the indicated viruses. Data are representative of at least two
independent experiments.
(D and E) C57Bl6 mice were infected with 1,000 PFU by the intranasal route of inoculation with the indicated viruses. On the indicated days
postinfection, lungs (D) and spleens (E) were harvested, disrupted, and titered on NIH 3T12 cells. The data were compiled from one or two experiments
with three to five mice analyzed per experiment. Data are shown as log10 titer, and the bar indicates the geometric mean titer. The dashed line
indicates the limit of detection of this assay as log101.7 or 50 PFU/ml of sample homogenate.
doi:10.1371/journal.ppat.0030011.g003
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during lytic expansion in the spleen.
Inhibition of NF-jB Signaling Impairs Establishment of
Splenic Latency
Since impairment of NF-jB signaling had no effect on virus
replication in the lung, yet slightly impaired acute replication
in the spleen, we next examined the role of NF-jB signaling
in the establishment of latency, as well as reactivation from
latency, in bulk splenocytes and speciﬁc splenocyte subpo-
pulations at early times postinfection. Mice were infected via
intranasal inoculation with 1,000 PFU of IjBaM.1, IjBaM.2,
IjBaM.MR, or WT cHV68. At 15 to 16 days postinfection
(dpi), splenocytes were isolated and the frequency of viral
genome–positive cells was determined by limiting-dilution
PCR analysis (Figure 4A). Unsorted, bulk splenocytes were
found to harbor viral genome at a frequency of one in 3,646
and one in 5,570 cells in mice infected with either the
IjBaM.1 and IjBaM.2 recombinant virus, respectively. This
was a signiﬁcantly lower frequency than that observed in mice
infected with either WT cHV68 (one in 138 cells) or
IjBaM.MR virus (one in 75 cells) (Figure 4A, summarized in
Table 1). This approximately 50-fold reduction represented a
greater than 96% decrease in the frequency of latently
infected cells in mice infected with the IjBaM-expressing
recombinant viruses compared to WT and marker rescue
control viruses, indicating that inhibition of NF-jB signaling
has a substantial impact on the ability of cHV68 to establish
latency in splenocytes following intranasal infection.
To determine the ability of splenocytes harboring the
IjBaM virus to reactivate virus, we quantitated ex vivo
reactivation of intact cells by limiting-dilution analysis on
MEFs as described in Materials and Methods. Splenocytes
from WT and IjBaM.MR-infected mice reactivated at a
frequency of one in 3,102 and one in 3,563, respectively
(Figure 4B). The frequency of reactivation of bulk splenocytes
from mice infected with IjBaM.1 and IjBaM.2 was signiﬁ-
cantly lower than control virus reactivation and required a
mathematical extrapolation of the best-ﬁt curve, leading to
estimated frequencies of one in 180,936 and one in 300,788
for IjBaM.1 and IjBaM.2, respectively (Figure 4B). The
amount of preformed infectious virus detected by plating
Figure 4. Splenic Latency Is Markedly Reduced in Mice Infected with 1,000 PFU of cHV68-IjBaM by the Intranasal Route of Inoculation
Bulk splenocytes or flow cytometry-sorted CD19
þ splenic cell populations were harvested from infected C57BL/6 mice at 15 or 16 dpi and analyzed by
limiting-dilution viral genome PCR (A and C) and limiting-dilution ex vivo reactivation assays (B and D) as described in Materials and Methods.
(A) Frequency of unsorted, bulk splenocytes harboring viral genomes.
(B) Frequency of unsorted, bulk splenocytes reactivating virus. Significant levels of preformed virus were not detected.
(C) Frequency of sorted CD19
þB cells harboring viral genome. Using a PE-conjugated antibody to the pan–B-cell marker CD19 (CD19-PE), splenic B cells
were separated into B-cell (CD19
þ) and non–B-cell (CD19
 ) populations isolated by FACS. Postsort FACS analysis indicated that the mean purities for
CD19
þ cells were 97.7 6 1.1% for WT and 96.7 6 3.4% for IjBaM.1.
(D) Frequency of sorted CD19
þB cells reactivating virus. For both limiting-dilution assays, curve fit lines were derived from nonlinear regression analysis,
and symbols represent the mean percentage of wells positive for virus (viral DNA or cytopathic effect) 6SEM. The dashed line represents 63.2%, from
which the frequency of viral genome–positive cells or the frequency of cells reactivating virus was calculated based on Poisson distribution. The data
shown represent three to five independent experiments with spleen cells pooled from five mice per experimental group. Where examined, the
frequency of splenocytes and CD19
þ B cells that harbored viral genome in mice infected with IjBaM.1 or IjBaM.2 was significantly different (p , 0.02)
from that of mice infected with WT or IjBaM.MR control viruses.
doi:10.1371/journal.ppat.0030011.g004
PLoS Pathogens | www.plospathogens.org January 2007 | Volume 3 | Issue 1 | e11 0102
Role of NF-jBi ncHV68 B-Cell Latencymechanically disrupted cells in parallel was negligible for all
samples. The reactivation frequencies of the IjBaM recombi-
nant viruses are approximately 50-fold lower than the
frequency of viral genome–positive cells, in close agreement
with the decrease in the frequency of viral genome–positive
splenocytes. Thus, the efﬁciency of virus reactivation is
similar for cells infected with the IjBaM recombinant viruses
and the control viruses.
It is unclear whether the residual levels of latency observed
in mice infected with the IjBaM expressing viruses represent
the infection of a population of cells that do not require NF-
jB activation for establishment of cHV68 latency or whether
they arise from latently infected cells in which the levels of
expression of IjBaM were not sufﬁcient to block NF-jB
activation. Unfortunately, it is not possible at this time to
distinguish between these alternatives. We also considered
the possibility that infection with the IjBaM-expressing
viruses could give rise in vivo to a revertant virus that has
lost the ability to express a functional IjBaM. To address this
possibility, independent isolates of virus (IjBaM.R1 and
IjBaM.R2) were recovered from ex vivo reactivation of
splenocytes harvested from IjBaM-infected mice and ana-
lyzed for the presence of the IjBaM expression cassette.
Southern blot analyses revealed that these viral genomes had
retained the IjBaM expression cassette (unpublished data).
More important, the viruses recovered from reactivated
splenocytes also retained their ability to inhibit NF-jB
activation in NIH 3T12 ﬁbroblasts (Figure 2B). Therefore,
the small population of cells that is viral genome–positive
appears to harbor virus capable of expressing IjBaM.
To examine the role of speciﬁc splenocyte cell populations,
bulk splenocytes were separated by ﬂuorescence-activated
cell sorting (FACS) into B-cell and non–B-cell populations
utilizing CD19 as a marker for B cells. This resulted in cell
Table 1. Frequencies of Cell Populations Harboring Viral Genomes
Virus Mouse
Strain
a
Route of
Infection
b
Organ dpi Cell
Population
Frequency of
Viral Genome–Positive
Cells (one in)
c
Total Number
of Cells
d
Total Number
of Genome-Positive
Cells
e
WT cHV68 C57BL/6 i.n. Spleen 15–16 Unsorted 138 1.3 3 10
8 930,000
B cell 98 7.3 3 10
7 750,000
Non–B cell 4,254 5.5 3 10
7 13,000
42–49 Unsorted 2,210 7.9 3 10
7 36,000
B cell 2,785 3.5 3 10
7 12,000
IjBaM.MR C57BL/6 i.n. Spleen 16 Unsorted 75 2.7 3 10
8 3,600,000
IjBaM.1 i.n. Spleen 15–16 Unsorted 3,646 1.2 3 10
8 34,000
B cell 4,093 6.8 3 10
7 16,000
Non–B cell 25,985 5.7 3 10
7 2,200
42–49 Unsorted 7,017 9.5 3 10
7 14,000
B cell 11,138 5.0 3 10
7 4,500
IjBaM.2 C57BL/6 i.n. Spleen 16 Unsorted 5,570 1.7 3 10
8 30,000
IjBaM.MR Tg(BCL2) i.n. Spleen 16 Unsorted 37 8.1 3 10
8 22,000,000
B cell 39 9.8 3 10
8 25,000,000
41–43 Unsorted 295 4.1 3 10
8 1,400,000
235 Unsorted 695 2.7 3 10
8 390,000
IjBaM.1 Tg(BCL2) i.n. Spleen 16 Unsorted 2,577 4.2 3 10
8 160,000
B cell 2,168 3.1 3 10
8 140,000
41–43 Unsorted 1,983 3.0 3 10
8 150,000
235 Unsorted 6,139 2.4 3 10
8 39,000
WT cHV68 C57BL/6 i.n. Lung 16 Unsorted 298 6.3 3 10
7 210,000
B cell 138 5.8 3 10
6 42,000
Non–B cell 236 5.7 3 10
7 240,000
IjBaM.1 C57BL/6 i.n. Lung 16 Unsorted 422 8.2 3 10
7 200,000
B cell 1,447 7.1 3 10
6 5,000
Non–B cell 552 7.5 3 10
7 140,000
IjBaM.MR C57BL/6 i.p. PEC 16 Unsorted 108 1.0 3 10
7 95,000
IjBaM.1 C57BL/6 i.p. PEC 16 Unsorted 166 1.2 3 10
7 73,000
IjBaM.MR C57BL/6 i.p. Spleen 16 Unsorted 85 2.4 3 10
8 2,800,000
IjBaM.1 C57BL/6 i.p. Spleen 16 Unsorted 327 1.2 3 10
8 360,000
aTg(BCL2) are heterozygous for Bcl-2 transgene expression from the immunoglobulin heavy chain enhancer and SV40 promoter on a C57BL/6 background.
bi.n., intranasal; i.p., intraperitoneal.
cFor experiments in C57BL/6 mice, the frequency data were determined from the mean of at least two independent experiments with cells from the indicated organs pooled from three to
five mice per experimental group for spleens and PECs or pooled from ten to 15 mice for lungs. For experiments in C57BL/6-Tg(BCL2) mice, frequency data were determined from the
mean of two independent experiments with splenocytes pooled from three to five mice per experimental group at 16 and 41 to 43 dpi and from the mean of four individual mice at 235
dpi.
dCell numbers were derived from the calculated total number of cells per organ and from the percentage of total cells that each subset represents, as calculated from FACS gating (CD19
þ
B cells, CD19
  non–B cells).
eDerived from the experimental frequency data and the approximate total number of cells per population.
doi:10.1371/journal.ppat.0030011.t001
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(unpublished data). As shown in Figure 4C and summarized in
Table 1, the CD19
þ B-cell population was found to harbor
viral genome–positive cells at a similar frequency as the bulk
splenocyte population following WT cHV68 infection. This is
consistent with previous reports that B cells comprise the
major reservoir of cHV68 latency in the spleen [2,27,42,43].
As observed with bulk splenocytes, CD19
þ B cells from mice
infected with IjBaM.1 had a drastic reduction in the
frequency of latently infected cells (one in 4,093) compared
to those from mice infected with WT (one in 98). This 40-fold
difference represents a 98% reduction in the establishment
of latency upon NF-jB inhibition, which was further
s u b s t a n t i a t e db ya ne s t i m a t e d9 8 %r e d u c t i o ni nt h e
frequency of CD19
þ cells reactivating virus in IjBaM.1-
infected mice compared to mice infected with WT (Figure
4D). The frequency of latently infected CD19
  non–B cells
was also diminished in mice infected with IjBaM.1 by 6-fold
(84% reduction) compared to those infected with WT virus
(Table 1). At this point, it is unclear whether the diminished
levels of latency in the non–B-cell population reﬂect a
dependence on B-cell latency for establishment of latency
in the non–B-cell reservoirs or whether there is a role for NF-
jB activation in the establishment of latency in the non–B-
cell reservoirs. Regardless, these data indicate that NF-jB
signaling is critical for the efﬁcient establishment of latency
in splenic B cells following intranasal inoculation.
Virus Replication Does Not Contribute to Changes in Viral
Load between Early and Intermediate Times Postinfection
Latency in WT-infected mice is characterized by a peak in
viral genome–positive splenocytes at 16 dpi, a rapid con-
traction of latently infected splenocytes that is apparent by 6
wk postinfection, followed by a more gradual rate of decline
throughout later time points as the virus reaches a steady-
state level in memory B cells [2]. However, some cHV68
mutants that exhibit signiﬁcant defects in the establishment
of splenic latency (measured at 16 dpi) fail to contract at the
same rate as WT virus and, as such, the frequency of latently
infected splenocytes often approaches the level observed with
WT virus infection at later times postinfection [44,45]. We
therefore examined the frequency of latently infected
splenocytes at 42 to 49 dpi (Figure 5A). In mice infected with
IjBaM.MR, the frequency of viral genome–positive, unsorted
splenocytes dropped 16-fold at 42 to 49 dpi from that
observed at day 16, similar to previous reports with WT
cHV68 [2,25]. In contrast, the frequency of unsorted
splenocytes latently infected with IjBaM.1 decreased only 2-
fold. Therefore, the frequency of viral genome–positive
unsorted splenocytes infected with IjBaM.1 (one in 7,017)
were only 3-fold lower than WT cHV68 (one in 2,210) by 42 to
49 dpi (p¼0.0146) (Figure 5A). As B cells represent the major
long-term reservoir of viral latency in the spleen, the
frequencies of genome-positive CD19
þ B cells for IjBaM.1
(one in 11,138) and WT virus (one in 2,785) were very similar
to the frequency of bulk splenocytes, where only a 4-fold
difference between the frequencies of IjBaM and WT virus
was apparent by 42 to 49 dpi (p ¼ 0.0198) (Figure 5A).
We hypothesized that the dissimilar rates of contraction of
latently infected splenocytes between IjBaM.1 and WT virus
could involve differences in cell turnover due to lytic events
and/or the reseeding of latency in the spleen by virus arising
from in vivo reactivation (between day 16 and later time
points) [46]. To assess whether virus reactivation and
reseeding of latency might be contributing to the results
observed at 42 to 49 dpi, we administered the antiviral drug
cidofovir to mice using a drug dosage demonstrated in
previous studies to effectively inhibit acute virus replication
and seeding of the spleen by day 16 after intranasal infection
Figure 5. cHV68-IjBaM–Infected Mice Have Decreased Splenic Latency at Later Timepoints after Intranasal Infection that Is Not Altered by Inhibiting
Lytic Replication
Bulk splenocytes or FACS-sorted CD19
þ splenic cell populations were harvested from infected C57BL/6 mice and analyzed by limiting-dilution viral
genome PCR.
(A) Frequency of unsorted, bulk and CD19
þB cells from mice infected with 1,000 PFU of WT cHV68 or IjBaM.1 harboring viral genomes at 42 and 49 dpi.
Postsort FACS analysis indicated that the mean purities for CD19
þ cells were 97.8 6 1.3% for WT and 98.5 6 1.5% for IjBaM.1. Data represent three
independent experiments with spleen cells pooled from five mice per experimental group. The frequency of splenocytes and CD19
þ B cells that
harbored viral genome in mice infected with IjBaM was significantly different from that of mice infected with WT virus in an unpaired t-test as follows: p
¼ 0.0146 (unsorted splenocytes) and p ¼ 0.0198 (CD19
þ).
(B) The effect of treatment with the antiviral drug cidofovir between 16 and 39 dpi on the frequency of viral genome–positive cells in mice infected with
IjBaM.MR or IjBaM.1. Mice were injected subcutaneously with 100 ll of PBS or with 25 mg/kg cidofovir (CDV) in 100 ll of PBS every 3 d between 16
and 39 dpi. Mice were weighed weekly, and dosage was adjusted. Data represent one (PBS) or two (CDV) independent experiments of three to six mice
per experimental group. The frequency of splenocytes that harbored viral genome in the mice infected with IjBaM.1 was significantly different (p ¼
0.0351) from that of mice infected with IjBaM.MR. Symbols represent the mean percentage of wells positive for virus (viral DNA) 6SEM.
doi:10.1371/journal.ppat.0030011.g005
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genome–positive cells in control mice (no cidofovir) infected
with the IjBaM.1 was 9-fold lower at 39 dpi compared to
control mice infected with IjBaM.MR (Figure 5B). Surpris-
ingly, the frequency of cells harboring viral genome in mice
treated with cidofovir was nearly indistinguishable from that
of the untreated mice infected with either IjBaM.1 or
IjBaM.MR. This argues that the decline in latency of the
IjBaM-expressing virus or the control IjBaM-MR virus
between 16 and 39 dpi does not involve any signiﬁcant
contribution from virus reactivation and reseeding of splenic
latency reservoirs and thus may reﬂect differences in
trafﬁcking of latently infected cells (see Discussion).
Bcl2 Does Not Rescue the Latency Defect Observed with
IjBaM-Expressing Viruses
Bcl-2 is an antiapoptotic molecule whose expression is
regulated by NF-jB. Notably, B-cell–speciﬁc expression of
Bcl-2 in transgenic mice overcomes NF-jB–dependent
requirements for mature B-cell development and survival in
the periphery but does not restore B-cell proliferation upon
mitogen activation [6]. To address the potential role of NF-jB
as a factor critical for peripheral B-cell survival during
cHV68 latency, we examined whether constitutive expression
of Bcl-2 in B cells could rescue the establishment of latency in
mice infected with IjBaM.1. On 16 dpi, there was an
approximately 2-fold increase in the frequency of viral
genome–positive unsorted splenocytes in Bcl-2 mice infected
with IjBaM.MR compared to the frequency in infected
C57BL/6 nontransgenic mice (Figure 6A and Table 1).
However, there was no dramatic increase in the frequency
of latency establishment in Bcl-2 mice infected with IjBaM.1
compared to infected C57BL/6 mice (Figure 6A and Table 1).
Thus, the frequency of bulk, unsorted splenocytes from Bcl-2
mice infected with IjBaM.1 (one in 2,577) was 70-fold lower
than the frequency of viral genome–positivity found in
IjBaM . M R - i n f e c t e dm i c e( o n ei n3 7 )( F i g u r e6 A ) .T h i s
correlated with an absence of splenomegaly in IjBaM.1-
Figure 6. Transgenic Expression of Bcl-2 in B Cells Does Not Rescue the Defect in Splenic Latency Establishment by cHV68-IjBaM after Intranasal
Infection
Bulk unsorted splenocytes or magnetic bead–enriched CD19
þ splenocytes from infected C57BL/6-Tg(BCL2) were analyzed by limiting-dilution viral
genome PCR (A, C, and D) and limiting-dilution ex vivo reactivation assays (B) as described in Materials and Methods.
(A) Frequency of unsorted, bulk splenocytes and CD19
þ B cells from mice infected with 1,000 PFU of IjBaM.MR or IjBaM.1 harboring viral genomes at
16 dpi. Using a PE-conjugated antibody to the pan–B-cell marker CD19 (CD19-PE), splenic B cells were separated into B-cell (CD19
þ) and non–B-cell
(CD19
 ) populations by magnetic activated cell sorting. Postsort FACS analysis indicated that the mean purities for CD19
þ cells were 97.4 for WT, and
96.5 6 1.5% for IjBaM.1. The frequency of splenocytes that harbored viral genome in mice infected with IjBaM was significantly different (p ¼ 0.05)
from that of mice infected with IjBaM.MR virus.
(B) Frequency of unsorted, bulk splenocytes and CD19
þ B cells reactivating virus from mice infected with 1,000 PFU of IjBaM.MR or IjBaM.1 at 16 dpi.
The frequency of splenocytes and CD19
þ B cells that harbored viral genome in mice infected with IjBaM was significantly different from that of mice
infected with IjBaM.MR in a t-test as follows: p ¼ 0.0460 (unsorted splenocytes) and p ¼ 0.0286 (CD19
þ).
(C) Frequency of unsorted, bulk splenocytes reactivating virus from mice infected with 1,000 PFU of IjBaM.MR or IjBaM.1 at 41 to 43 dpi. CD19
þB cells
comprise greater than 67% of total splenocytes as determined by FACS analysis.
(D) Frequency of unsorted, bulk splenocytes reactivating virus from mice infected with 1,000 PFU of IjBaM.MR or IjBaM.1 at 235 dpi. FACS analysis
indicated that the unsorted splenocytes were composed of 66.3 6 2.0% (IjBaM.MR) and 60.3 6 7.7% (IjBaM.1) CD19
þ B cells. Symbols represent the
mean percentage of wells positive for virus (viral DNA or cytopathic effect) 6SEM. The data shown represent two independent experiments with cells
pooled from three to five mice per experimental group (16 and 41 to 43 dpi) or one experiment with four individual mice at 235 dpi.
doi:10.1371/journal.ppat.0030011.g006
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Role of NF-jBi ncHV68 B-Cell Latencyinfected mice as determined by spleen weight compared to
uninfected mice (1.1-fold increase), while there was notable
splenomegaly in the IjBaM.MR-infected mice (2.2-fold
increase) (unpublished data).
Bcl-2 mice are characterized by a higher proportion of B
cells in lymphoid organs, which represented 72% of the total
splenocytes at 16 dpi in these studies. To further characterize
latency in these transgenic mice, splenocytes harvested at 16
dpi were separated into CD19
þ and CD19
  populations. As
expected, the frequencies of CD19
þ B cells harboring virus
for both IjBaM.1 (one in 2,168) and IjBaM.MR (one in 39)
(Figure 6A) were nearly identical to the frequencies observed
with bulk splenocytes.
Since B cells from Bcl-2 transgenic mice are known to
survive for a longer period of time in cell culture upon
explant, we assessed whether latently infected splenocytes
from Bcl2 mice would reactivate at a higher frequency than
those recovered from C57BL/6 mice. Unsorted and CD19
þ B
cells were plated for ex vivo reactivation analyses at 16 dpi. As
observed for splenocytes in the C57BL/6 mice, bulk splenoc-
tyes from IjBaM.MR-infected Bcl2 mice had a similar 50-fold
reduction in frequency of cells reactivating virus compared to
the frequency of cells harboring viral genome (Figure 6B and
summarized in Table 2). The reactivation of puriﬁed CD19
þB
cells were reduced approximately 3- to 4-fold compared to
bulk splenocytes, a decrease that may reﬂect the time and
manipulation required to purify these cells. The frequency of
unsorted and CD19
þ splenocytes recovered from IjBaM.1-
infected mice was approximately 50-fold lower than observed
with the marker rescue virus (Figure 6B and Table 2). Taken
together, these data conﬁrm the major defect in latency
establishment by IjBaM.1 and argue that inhibiting NF-jB
regulation of Bcl-2 expression alone does not account for the
phenotype of the IjBaM-expressing viruses. In addition, since
no difference in the efﬁciency of spontaneous virus reac-
tivation was observed with latently infected splenocytes
harvested from Bcl-2 transgenic mice compared to C57Bl/6
mice, this indicates that survival of latently infected B cells in
culture does not play a signiﬁcant role in dictating the
observed frequency of splenic B cells reactivating virus.
Extending the analysis of latency in Bcl-2 transgenic mice,
we observed at later times postinfection that there was a
slightly greater defect in latency in Bcl-2 trangenic mice
infected with IjBaM.1 (one in 1,983) compared to IjBaM.MR
(one in 295) (Figure 6C) than observed in C57BL/6 mice. This
defect was also maintained at 235 dpi with a nearly 10-fold
difference (p ¼ 0.0181) between the frequency of viral
genome–positive splenocytes from mice infected with
IjBaM.1 (one in 6,139) and IjBaM.MR (one in 695) (Figure
6D). In addition, these data are consistent with the
interpretation that there is a steady rate of decay in the B-
cell reservoir over time for both IjBaM.1 and IjBaM.MR
once the initial contraction phase between 16 and 41 dpi
occurs. Taken together, the lack of complementation by Bcl-2
at any time point after infection indicates that NF-jB
signaling likely provides a role distinct from peripheral B-
cell survival during cHV68 latency.
Inhibition of NF-jB Activation Reduces Latency in Lung
B Cells
Recent reports indicate that lung B cells are infected early
after virus inoculation and may represent a long-term
reservoir for viral persistence [29,48,49]. As B cells are critical
for acute replication and seeding of the spleen at early times
after infection [21,22], we hypothesized that the approx-
imately 50-fold reduction of splenic latency in mice infected
with IjBaM.1 might be due to a reduction in seeding of the
spleen from cHV68-infected lung B cells. Indeed, acute virus
Table 2. Frequencies of Cell Populations Reactivating Virus at 15 to 16 dpi
Virus Mouse
Strain
a
Route of
Infection
b
Organ Cell
Population
Frequency of
Reactivating Cells (1 in)
c
Total Number
of Cells
d
Total Number
of Reactivating Cells
e
WT cHV68 C57BL/6 i.n. Spleen Unsorted 1,302 1.3 3 10
8 41,000
B cell 12,993 7.3 3 10
7 5,600
IjBaM.MR C57BL/6 i.n. Spleen Unsorted 3,563 2.7 3 10
8 76,000
IjBaM.1 C57BL/6 i.n. Spleen Unsorted 180,936
f 1.2 3 10
8 690
B cell 435,307
f 6.8 3 10
7 160
IjBaM.2 C57BL/6 i.n. Spleen Unsorted 300,788
f 1.7 3 10
8 560
IjBaM.MR Tg(BCL2) i.n. Spleen Unsorted 1,985 8.1 3 10
8 930,000
B cell 7,554 9.8 3 10
8 750,000
IjBaM.1 Tg(BCL2) i.n. Spleen Unsorted 109,445
f 4.2 3 10
8 3,800
B cell 275,127
f 3.1 3 10
8 1,100
WT cHV68 C57BL/6 i.p. PEC Unsorted 587 8.4 3 10
6 14,000
IjBaM.MR C57BL/6 i.p. PEC Unsorted 453 1.0 3 10
7 23,000
IjBaM.1 C57BL/6 i.p. PEC Unsorted 1,065 1.2 3 10
7 11,000
WT cHV68 C57BL/6 i.p. Spleen Unsorted 14,925 1.0 3 10
8 6,700
IjBaM.MR C57BL/6 i.p. Spleen Unsorted 14,925 2.4 3 10
8 16,000
IjBaM.1 C57BL/6 i.p. Spleen Unsorted 113,987
f 1.0 3 10
8 910
aC57BL/6-Tg(BCL2) are heterozygous for Bcl-2 transgene expression from the immunoglobulin heavy chain enhancer and SV40 promoter.
bi.n., intranasal; i.p., intraperitoneal.
cDetermined from the mean of at least two independent experiments with cells from the indicated organs pooled from three to five mice per experimental group.
dCell numbers were derived from the calculated total number of cells per organ and from the percentage of total cells that each subset represents, as calculated from FACS gating (CD19
þ
B cells).
eDerived from the experimental frequency data and the approximate total number of cells per population.
fAbsolute frequency numbers fell below 63.2% and were determined by extrapolation of the line of best fit.
doi:10.1371/journal.ppat.0030011.t002
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IjBaM.1 grew more poorly in the spleens of infected mice
compared to IjBaM.MR (Figure 2E), even though IjBaM.1
exhibited WT replication kinetics in the lungs (Figure 3D).
This suggested the possibility of a defect in trafﬁcking of
infected B cells from the lung to the spleen and led us to
investigate the ability of IjBaM.1 to establish latency in
unsorted lung cells and B cells (CD19
þ) at 16 dpi.
At 16 dpi, there were nearly equivalent frequencies of viral
genome–positive unsorted lung cells in mice infected with
IjBaM.1 (one in 422) and WT cHV68 (one in 298) (Figure 7A).
CD19
þ (B cells) and CD19
  (non–B cells) were enriched from
the bulk lung cells and analyzed for the presence of viral
genome by limiting-dilution PCR. Non–B cells harbored
nearly identical frequencies of viral genomes (Figure 7B).
However, as shown in Figure 7C, lung B cells from IjBaM.1
(one in 1,447)-infected mice had signiﬁcantly decreased levels
of viral genomes compared to mice infected with WT virus
(one in 138) (p ¼ 0.0316). This represents an approximately
90% reduction in the frequency of viral genome–positive
lung B cells in mice infected with the IjBaM.1 recombinant
virus (Table 1). Because it has been shown that increasing the
dose of virus inoculation can overcome the defect in latency
establishment of a virus containing a stop mutation in the
latency-associated M2 gene [44], we increased the dose of
virus 100-fold to 1310
5 PFU and examined infection of lung
B cells by limiting-dilution PCR analysis of FACS-sorted
CD19
þ cells (B cells). Notably, lung B cells from mice infected
with IjBaM.1 exhibited a 15-fold reduction in the establish-
ment of latency, even with the higher inoculating dose (Figure
7D). These data indicate that mice infected with a virus that
inhibits NF-jB activation exhibit a signiﬁcant reduction in
the establishment of latency in B cells of the lung, a
phenotype which could not be overcome by increasing the
inoculating dose of virus. It should be noted that the
magnitude of the defect observed with the IjBaM-expressing
virus in the lungs (10- to 15-fold) was less than that observed
in the spleen (approximately 50-fold), suggesting that in
addition to playing a role in the establishment of B-cell
latency, NF-jB activation also plays a role in subsequent
Figure 7. IjBaM.1-Infected Mice Have Decreased Latency in Lung B Cells 16 dpi after Intranasal Infection
Bulk lung cells, or lung cell subsets, were harvested from infected C57BL/6 mice at 16 dpi and analyzed by limiting-dilution viral genome PCR as
described in Materials and Methods.
(A) Frequency of unsorted, bulk lung cells harboring viral genomes.
(B) Frequency of CD19
  non–B cells harboring viral genomes. Using a PE-conjugated antibody to the pan–B-cell marker CD19 (CD19-PE), splenic B cells
were separated into B-cell (CD19
þ) and non–B-cell (CD19
 ) populations by magnetic activated cell sorting. Postsort FACS analysis indicated that the
mean purities for CD19
  cells were 97.2 6 2.4% for WT cHV68 and 98.7 6 0.9% for IjBaM.1.
(C) Frequency of subsets enriched for CD19
þ B cells harboring viral genome. Subsequent to magnetic separation, postsort FACS analysis indicated that
the mean purities for CD19
þ cells were 82.3 6 0.5% for WT cHV68 and 82.0 6 1.3% for IjBaM.1. Given that in presort FACs analysis CD19
þ cells
comprised approximately 9% of the lung cell suspension, magnetic separation generated a 9-fold enrichment of CD19
þ B cells. The data shown
represent three independent experiments with spleen cells pooled from 12 to 15 mice per experimental group. The frequency of splenocytes and
CD19
þB cells that harbored viral genome in mice infected with IjBaM was significantly different (p¼0.0316) from that of mice infected with WT viruses.
(D) Frequency of FACS sorted CD19
þ B cells harboring viral genomes in the lungs of mice infected with 1310
5 PFU of IjBaM.MR or IjBaM.1. Postsort
FACS analysis indicated that the purity of the CD19
þ cell population was 86% for IjBaM.MR and 93% for IjBaM.1. The data shown represent a single
experiment with 15 mice per group. Curve fit lines were derived from nonlinear regression analysis, and symbols represent the mean percentage of
wells positive for virus (viral DNA) 6SEM.
doi:10.1371/journal.ppat.0030011.g007
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lung to the spleen and subsequent establishment of splenic
latency.
Decreased B-Cell Activation in the Lungs and Spleen of
IjBaM-Infected Mice
NF-jB is well known for its role in recruiting immune cells
by driving the expression of inﬂammatory cytokines, chemo-
kines, adhesion molecules, and inﬂammatory mediators. To
determine whether inhibition of NF-jB signaling in IjBaM-
infected mice impacts the global immune response, we
assessed the phenotypes of B and T cells in the lungs and
spleens 16 and 42 dpi with 1,000 PFU of IjBaM.1 and WT
virus. The number of B cells (8.2% versus 12.4%, p ¼ 0.0548),
CD4
þT cells (9.6% versus 12.9%, p¼0.1065), and CD8
þT cells
(12.9% versus 18.1%, p ¼ 0.0268) present in the lungs of
IjBaM.1-infected mice was slightly diminished at 16 dpi
compared to WT virus–infected mice (Table 3; unpublished
data). However, there was no signiﬁcant difference in the
activation state of T cells as determined by upregulation of
CD11a (unpublished data). Notably, the relatively small
difference in the number of B cells present in the lungs is
unlikely to contribute signiﬁcantly to the observed decrease
in establishment of B-cell latency in mice infected with the
IjBaM.1 virus.
To assess whether there were phenotypic differences
between the B-cell populations in IjBaM.1- and WT virus–
infected mice, CD19
þ lung and splenic B cells were analyzed
for markers of isotype-class switching (IgD
 ), germinal center
participation (PNA
hi), proliferation (Ki67
þ), and activation
(CD69
hi) at 16 and 42 dpi (Table 3). The total number of B
cells and the frequency of IgD and PNA
hi CD19
þ B cells were
slightly lower in the lungs of IjBaM.1-infected mice com-
pared to control virus. The proliferation of B cells in the
lungs of infected mice was also examined by the measuring
bromodeoxyuridine incorporation. Mice were administered
bromodeoxyuridine in their drinking water from 8 to 16 dpi;
no signiﬁcant difference in the frequency of B cells
incorporating bromodeoxyuridine was observed in IjBaM.1
virus–infected mice compared to IjBaM.MR virus–infected
mice (unpublished data). The only signiﬁcant difference in B
cells from mice infected with IjBaM.1 compared to WT virus
at 16 dpi was a decreased frequency of CD19
þCD69
hi B cells
(Figure 8A). In both the lung (p ¼ 0.0003) and spleens (p ,
0.0001), there was an approximately 3-fold reduction in
CD69
hi B cells in IjBaM.1-infected mice compared to mice
infected with IjBaM.MR at day 16 (Figure 8B). By 42 dpi, the
frequency of CD69
hi B cells in mice infected with either WT
virus or the IjBaM.1 virus was not signiﬁcantly different from
that observed in uninfected mice (Figure 8). Since CD69 is
known to play an important role in lymphocyte trafﬁcking,
the difference in CD69 levels between IjBaM.1 and WT virus
may contribute to the more severe latency phenotype
observed in splenic B cells compared to lung B cells at 16
dpi [50]. However, it is important to note that (i) only
approximately 1% of B cells at day 16 are cHV68 latently
infected and thus the vast majority of the CD69
þ B cells are
not virus infected and (ii) we currently do not have the
necessary tools to assess the status of CD69 expression on
latently infected B cells.
Intraperitoneal Inoculation of IjBaM.1 Partially Rescues
the Defect in EStablishment of Splenic Latency
Although increasing the dose of virus used to inoculate
mice via the intranasal route did not rescue the defect in
establishment of B-cell latency in the lungs observed with the
IjBaM.1, we addressed whether altering the route of
inoculation might have an impact on the establishment of
latency. The kinetics of IjBaM.1 replication in the spleen was
compared to IjBaM.MR and WT virus following intraper-
itoneal inoculation of mice with 1,000 PFU of virus. At days 4
and 9 after intraperitoneal inoculation with 1,000 PFU,
spleens were harvested and titered. Mice infected with
IjBaM.1 had comparable replication kinetics to WT virus at
4 dpi and slightly lower acute viral titers in the spleen
compared to those infected with IjBaM.MR (Figure 9A).
Surprisingly, there was a signiﬁcant reduction in detectable
virus replication in the spleens of mice infected with IjBaM.1
at 9 dpi compared to IjBaM.MR (p , 0.0001) and WT virus (p
, 0.0001) (Figure 9A). This indicates that IjBaM.1 is impaired
in the duration of acute replication compared to IjBaM.MR
and WT virus in the spleens of mice infected by the
intraperitoneal route. Notably, a shortened period of acute
phase replication has previously been observed for some
Table 3. Analysis of B-Cell Phenotype by Surface Antigen Markers in Infected C57BL/6 Mice
Organ Virus
a dpi CD19
þb CD19
þIgD
 c CD19
þPNA
hi CD19
þKi67
þ CD19
þCD69
hi
Lung Naı ¨ve 12.9 (4.1) 24.1 (5.1) 20.1 (7.6) 13.9 (0.42) 14.2 (6.12)
WT cHV68 16 12.4 (2.2) 42.5 (3.7) 28.5 (2.4) 20.9 (2.3) 42.7 (6.4)
IjBaM.1 16 8.2 (2.2) 35.2 (7.3) 25.1 (2.0) 19.8 (0.21) 16.1 (7.2)
WT cHV68 42 18.1 (4.9) 24.3 (3.2) 33.4 (5.0) 10.1 (1.1) 14.4 (5.0)
IjBaM.1 42 12.8 (2.1) 19.5 (1.9) 23.8 (4.4) 7.2 (0.17) 9.5 (0.77)
Spleen Naı ¨ve 50.9 (2.4) 17.9 (0.43) 6.4 (1.5) 16.9 (0.28) 6.8 (2.6)
WT cHV68 16 43.1 (2.3) 31.1 (1.6) 11.1 (0.84) 25.9 (1.8) 28.7 (3.2)
IjBaM.1 16 50.7 (2.4) 29.9 (3.0) 14.4 (1.3) 28.4 (3.5) 11.9 (2.3)
WT cHV68 42 37.4 (8.6) 16 (2.3) 6.0 (1.6) 15.7 (2.6) 8.2 (0.86)
IjBaM.1 42 38.0 (3.6) 12.9 (1.4) 7.1 (0.82) 10.4 (0.35) 5.9 (0.92)
aMice were infected with 1,000 PFU of the indicated viruses by intranasal inoculation.
bCell subsets were derived from initial FACS gating on live lymphocyte populations of cell preparations from the indicated organs. The data shown are the mean percentage values for
each subset determined from FACS analysis of four or five individual mice. Numbers in parentheses represent 6SD.
cCell subsets were derived from initial gating on CD19
þ cells and then further fractionated into the indicated subsets using a second surface marker as indicated.
doi:10.1371/journal.ppat.0030011.t003
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Role of NF-jBi ncHV68 B-Cell Latencyother cHV68 mutants that are not impaired in the establish-
ment of splenic latency [51–53], indicating that a decreased
duration of acute replication in the spleen does not directly
correlate with the levels of splenic latency that are established
following intraperitoneal inoculation. Since no defect in
virus replication in the lungs was observed following the same
dose of virus administered via intranasal inoculation (see
Figure 3B), this argues that there are distinct requirements
for acute virus replication at different anatomical sites.
To assess the establishment of viral latency, we initially
examined latency in peritoneal exudate cells (PECs). PECs
were harvested from infected mice at 16 dpi and the
frequency of cells harboring virus was determined by limit-
ing-dilution PCR. The frequency of viral genome–positive
PECs in mice infected with IjBaM.1 (one in 166 cells) was
nearly equivalent to the frequency of observed in mice
infected with IjBaM.MR (one in 108 cells) (Figure 9B). The
frequency of PECs that reactivated virus from mice infected
with IjBaM.1 (one in 1,065), IjBaM.MR (one in 453), and WT
(one in 587) viruses was nearly identical and was approx-
imately 5-fold lower than the frequency of viral genome–
positive cells (Figure 9D). As macrophages comprise the
majority of the cHV68-infected cells in the peritoneum of
mice [26], these results indicate that NF-jB activation is not
likely required for the establishment of latency, or for
reactivation, from latently infected macrophages. Impor-
tantly, we did not detect any preformed infectious virus in the
disrupted PEC samples (unpublished data).
Figure 8. Activated B Cells Are Decreased in the Lungs and Spleens of IjBaM-Infected Mice
Cells were prepared from the lungs and spleens harvested from four uninfected naı ¨ve mice or from four or five mice that were infected 16 and 42 d
prior to harvest with 1,000 PFU of WT cHV68 or IjBaM.1. Cells from individual mice were surface stained with anti-CD19 conjugated to allophycocyanin
and anti-CD69 conjugated to FITC and analyzed by flow cytometry.
(A) Flow cytometric dotplots of stained cells from the lungs (upper panel) and spleens (lower panel). Values shown in the upper right quadrant of each
dotplot are the percentages of CD19
þ cells that express the CD69 activation marker in a representative experimental sample.
(B) Each point in the scatterplot represents the percentage of CD19
þCD69
hi cells from the lung of a single mouse; the bar represents the mean
percentage. The percentage of CD19
þCD69
hi cells in the lungs of mice infected with IjBaM.1 was significantly different from that of mice infected with
WT cHV68; p ¼ 0.0007 at 16 dpi.
(C) Each point in the scatterplot represents the percentage of CD19
þCD69
hi cells from the spleen of a single mouse; the bar represents the mean
percentage. The percentage of CD19
þCD69
hi cells in the spleens of mice infected with IjBaM.1 was significantly different from that of mice infected
with WT cHV68; p , 0.0001 at 16 dpi and p ¼ 0.0042 at 42 dpi.
doi:10.1371/journal.ppat.0030011.g008
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activation on the establishment of splenic latency at day 16
post intraperitoneal inoculation (Figure 9C). Splenocytes
from mice infected with IjBaM.1 were found to harbor viral
genome at a frequency of one in 327 splenocytes, a 4-fold
decrease in establishment compared to a frequency of one in
85 splenocytes upon IjBaM.MR infection (p ¼ 0.0437). The
frequency of splenocytes reactivating virus from IjBaM.MR-
and WT virus–infected mice was nearly identical (one in
14,925), while the frequency of splenocytes reactivating virus
from IjBaM.1-infected mice was estimated to be one in
113,987, an approximately 8-fold decrease in the levels of
reactivating virus compared to IjBaM.MR-infected mice
(Figure 9E). The latter results are in close agreement with
the defect in the establishment of viral latency. Importantly,
the defect in establishment of splenic latency following
intraperitoneal inoculation of the IjBaM recombinant virus
was signiﬁcantly less than that observed following intranasal
inoculation (see Figure 4), which may be related to differ-
ences in virus trafﬁcking, target B-cell populations, and/or
transgene expression (see Discussion).
Figure 9. Route- and Tissue-Dependent Requirement for NF-jB
C57Bl6 mice were infected with 1,000 PFU by the intraperitoneal route of inoculation with the indicated viruses.
(A) On 4 and 9 dpi, spleens were harvested, disrupted, and titered on NIH 3T12 cells. The data are compiled from two (IjBaM.MR and WT) or four
(IjBaM.1) experiments with four or five mice per group. Asterisks denote that the acute splenic titers for IjBaM.1 differed significantly from IjBaM.MR
on day 4 (p ¼ 0.0036) and from IjBaM.MR (p , 0.0001) and WT (p , 0.0001) on day 9, as determined by the Mann-Whitney nonparametric test.
(B) Frequency of PECs harboring viral genomes.
(C) Frequency of unsorted, bulk splenocytes harboring viral genome.
(D) Frequency of PECs reactivating virus.
(E) Frequency of splenocytes reactivating virus. For both limiting-dilution assays, curve fit lines were derived from nonlinear regression analysis, and
symbols represent the mean percentage of wells positive for virus (viral DNA or cytopathic effect) 6SEM. The data shown represent three to five
independent experiments with cells pooled from five mice per experimental group.
doi:10.1371/journal.ppat.0030011.g009
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Here we report several novel ﬁndings regarding the role of
NF-jB signaling in gammaherpesvirus pathogenesis. First,
cHV68 activated NF-jB in the course of a productive
infection, yet did not require NF-jB signaling for productive
replication in murine ﬁbroblasts in tissue culture or during
acute replication in the lung in vivo. Second, NF-jB
activation was required for the efﬁcient establishment of
latency in B cells of the lung and spleen, and this decrease in
latency correlated with a reduction of CD69
hiCD19
þ B cells
following intranasal inoculation. Third, we found no evidence
for the contribution of virus reactivation and reseeding of
latency to the slower rate of contraction of the latently
infected reservoir in the spleen (observed between 2 and 6 wk
postinfection) of mice infected with the IjBaM-expressing
virus versus WT cHV68. Fourth, constitutive expression of
the antiapoptotic Bcl-2 protein in B cells did not rescue the
defect in establishment of splenic latency observed with the
cHV68-IjBaM–expressing virus at early or late times post-
infection. Finally, upon intraperitoneal inoculation, NF-jB
activation is required for sustained acute phase replication,
yet its inhibition resulted in a less severe impairment in the
establishment of splenic latency. Taken together, these data
demonstrate that NF-jB activation plays an important role in
the establishment of latency by cHV68.
NF-jB Is Activated but Not Required for
cHV68 Replication
Overexpression of the NF-jB subunit p65 inhibits the
progression of cHV68 lytic replication in 293T cells [33]. The
inhibition by p65 may relate to its ability to inhibit
transactivation of promoters by cHV68 replication and
transcription activator (RTA), as reported for KSHV RTA
[33,54]. Thus, a virus that inhibits NF-jB and does not
antagonize RTA might be predicted to have faster replication
kinetics, similar to a cHV68 mutant that expresses RTA
constitutively [55]. Indeed, the inability to detect cHV68–
IjBaM replication in the spleen 9 d after intraperitoneal
inoculation could be attributed to a more rapid peak of acute
phase replication (Figure 9A). However, unlike the results
reported with a dysregulated RTA-cHV68 mutant [55], IjBaM
had no signiﬁcant alteration in the kinetics of growth in
ﬁbroblast cells in culture and did not exhibit heightened peak
titers in the lungs after intranasal inoculation (Figure 3).
These data highlight a tissue-dependent requirement for NF-
jB during productive replication but do not support an
increase in lytic kinetics as an explanation for the substantial
decrease in splenic latency upon intranasal infection with
cHV68-IjBaM.
Role of NF-jB in the Efficient Establishment of
Splenic Latency
CD40L, BAFF, and lymphotoxin are costimulatory signals
provided by dendritic cells and T cells in germinal centers
that are required to drive NF-jB activation for B-cell survival
upon activation and differentiation [56]. Given that cHV68
establishes latency in B cells bearing surface markers
characteristic of cells proliferating and participating in
germinal center reactions [2,30,31], NF-jB is likely required
upon activation for proliferation of the infected cells.
Examination of splenocytes determined that infection with
cHV68-IjBaM resulted in a substantial (97%) inhibition in
the establishment of latency 16 dpi in comparison to WT
virus (Figure 4 and Table 1). We also determined the
frequency of latently infected cells in B-cell and non–B-cell
subpopulations; cHV68-IjBaM had a larger deﬁcit in splenic
establishment in B cells (98% reduction) compared to non–B
cells (83% reduction).
The lack of absolute ablation of latency upon infection
with IjBaM might reﬂect (i) the utilization of alternative NIK/
IKK1-mediated NF-jB activation, (ii) the establishment of
virus infection in cell populations that do not rely on NF-jB,
and/or (iii) inadequate expression of the IjBaM transgene;
the HCMV immediate-early promoter might not drive
sufﬁcient levels of IjBaM expression in some cells or cell
populations (as such, the residual latency observed at 16 dpi
might simply reﬂect a population of cells in which NF-jB
activation was not suppressed). Regardless, utilization of the
transdominant IjBaM clearly had a substantial impact on the
ability of cHV68 to establish latency in vivo.
In a mixed CD40
þCD40
  bone marrow chimeric system,
both CD40-deﬁcient and CD40-sufﬁcient B cells were found
to harbor viral genomes at 14 dpi at similar frequencies [3].
However, over time, latently infected CD40-deﬁcient B cells
were lost. This is consistent with an interpretation for a
requirement for CD40-mediated signaling and participation
in germinal centers of infected mice for long-term main-
tenance of cHV68 B-cell latency [3]. In contrast to the failure
to maintain latency in CD40-deﬁcient B cells at later
timepoints [3], cHV68-IjBaM–infected B cells exhibit a defect
in the establishment of latency at 16 dpi. This indicates that
activation of NF-jB plays a critical role in addition to, and
prior to, the engagement of infected cells with CD40L in
germinal center reactions. Thus, the impairment in the
establishment of splenic latency at 16 dpi in mice infected
with the recombinant cHV68-expressing IjBaM strongly
suggests that NF-jB activation mediated by the classic
pathway is essential for the efﬁcient establishment of latency
at early time points.
Upon encountering antigen, NF-jB functions in mature B
cells as a survival factor by mediating the upregulation of
several antiapoptotic proteins, including A1, Bcl-2, and Bcl-
xL [7,57]. One explanation for the large defect in latency
establishment is that the inhibition of NF-jB results in the
loss of expression of antiapoptotic proteins, such as Bcl-2 or
Bcl-xL, leading to cell death. Bcl-2 knockout mice lack mature
B cells in the periphery, demonstrating a role for Bcl-2 in
peripheral B-cell survival [58]. Transgenic mice with targeted
expression of Bcl-2 in B cells are characterized by larger
numbers of B cells and reduced apoptosis in germinal
centers, leading to an accumulation of memory B cells with
a low frequency of somatic hypermutation [59–61]. Bcl-2 and
Bcl-xL reduce apoptosis in resting and activated crel
 /  and
nfkb1
 /  mature B cells but do not restore proliferative
responses in response to mitogenic stimuli [62,63]. Although
Bcl-2 complemented BAFF
 /  mice for peripheral B-cell
survival, it did not restore differentiation and marginal zone
B cells [64]. Similarly, BAFF-R–deﬁcient mice expressing the
Bcl-2 transgene remain defective in the formation of
lymphoid follicles and germinal centers [65]. Taken together,
Bcl-2 transgenic mice might be expected to rescue a latency
defect for cHV68-IjBaM if NF-jB is required for survival in
the periphery but would be unlikely to rescue a defect in
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nal center reactions.
As shown here (see Figure 6), in the presence of both the
endogenous virally encoded bcl2 homolog (M11) and con-
stitutive expression of the cellular Bcl-2 in B cells, the deﬁcit
in latency establishment was still observed. cHV68-IjBaM
exhibited a 99% reduction in latency establishment in these
mice (both in bulk splenocytes and in puriﬁed B cells)
compared to IjBaM.MR at 16 dpi (Table 1). cHV68-IjBaM
viral load remained 10-fold lower than IjBaM.MR at 6 wk and
even through 7 mo after infection. The lack of latency
restoration for cHV68-IjBaM in the Bcl-2 transgenic mice
indicates that NF-jB plays a critical role(s) in addition to cell
survival.
The complementation of cell survival, but not prolifer-
ation, in response to mitogenic stimulation by the bcl-2
transgene in c-rel
 /  B cells indicates that NF-jB likely
functions to promote cell cycle progression in a Bcl-2–
independent manner [63]. c-rel
 /  B cells fail to enter S phase
upon B-cell receptor activation, a block in cell cycle
progression that is attributed to the failure to induce the
transcription of G1 cyclins D3 and E, which in turn leads to a
loss of cdk activity and delayed pRB phosphorylation [66].
NF-jB activation likely mediates important roles in cell cycle
progression that are required during the proliferative
expansion of cHV68-infected B cells in the spleen [31,32].
Maintenance of cHV68 Latency
An examination of the maintenance of long-term latency at
6 wk postinfection demonstrated, as previously observed, a
signiﬁcant contraction in splenic latency from 16 to 42 dpi
for WT and marker rescue, in both C57BL/6 and Bcl-2
transgenic mice. However, a similar magnitude of contraction
of splenic latency was not observed in cHV68-IjBaM–
infected mice. The end result is that the latency defect of
the cHV68-IjBaM virus is diminished at later times post-
infection. Similar observations have been made for other
cHV68 mutants, including viruses with targeted mutations in
the M2, M4, gp150, and viral TK genes [44,45,51,67,68], all of
which exhibit severe latency establishment phenotypes at day
16 postinfection but less substantial latency phenotypes at
later times postinfection. The slower decline in splenic
latency for cHV68-IjBaM might be attributed to (i) a delay
in virus (or latently infected cell) trafﬁcking from the lung to
the spleen, (ii) a contribution of virus (or latently infected
cells) from nonsplenic reservoirs of latency that supplements
infected cell turnover in the spleen, (iii) direct infection of a
more stable, nonproliferating reservoir of cells (e.g., memory
B cells), (iv) an accumulation of virus in one particular subset
of cells that compensates for loss in another, and/or (v)
altered trafﬁcking of latently infected cells from the spleen to
other sites (egress). Cidofovir treatment of B-cell–deﬁcient
mice between 16 and 42 dpi has been demonstrated to reduce
viral latency in PECs and splenocytes after intraperitoneal
infection [46,47]. In contrast, utilizing the same treatment
regimen in C57BL/6 mice infected with the IjBaMo r
IjBaM.MR virus, there was no change in the levels of viral
latency in the spleens of mice following antiviral therapy
from 16 to 39 dpi. These data are consistent with the
interpretation that virus reactivation and seeding of the
spleen from alternative reservoirs does not contribute to
splenic latency at 6 wk postinfection. It is possible that the
IjBaM-expressing cHV68 may directly infect a nonprolifer-
ative stable cell reservoir, such as memory B cells, that is
detected at all time points.
Route-Specific Requirements for NF-jB Activation in the
Establishment of Splenic Latency
We have previously observed route-dependent phenotypes
for a cHV68 mutant in which the M2 gene has been disrupted
[44,51]. Similarly, when mice were infected via intraperito-
neal inoculation, a distinctly different phenotype of the
cHV68-IjBaM was observed. By this route, acute phase
replication at 9 dpi was nearly undetectable compared to
WT or MR, yet these altered kinetics did not substantially
affect the establishment of latency in the PEC or splenocytes
by the IjBaM virus at 16 dpi. Instead, the defect in the
establishment of splenic latency was more modest than
observed following intranasal inoculation (compare Figures
4 and 9).
A disconnect between lytic replication and latency estab-
lishment following intraperitoneal inoculation has been
reported for other cHV68 mutants (e.g., a cHV68 mutant
lacking 9.5 kb at the left end of the genome [53], a cHV68
mutant containing a stop mutation in the M2 ORF [51], or a
cHV68 mutant containing an insertion of a LacZ expression
cassette in the M1 ORF [52]). Interestingly, mice lacking B
cells do not maintain acute replication of WT cHV68 in the
spleen at day 9 following intraperitoneal infection, yet the
spleens do harbor signiﬁcant levels of latently infected cells at
later timepoints [22,43]. This indicates a role for B cells in
prolonging the acute phase of lytic replication, perhaps via
reactivation and seeding permissive cells in the spleen.
However, it is notable that B cells appear dispensable for
the establishment of latency in other cell types in the spleen
(e.g., dendritic cells and macrophages) [22]. Further charac-
terization of the kinetics of mutant virus replication and the
induction of the host immune response are required to
understand the basis for the more rapid clearance of acute
virus replication in the spleen for the IjBaM-expressing
virus. Regardless of the mechanism for the shortened acute
phase of replication, we can infer that the virus has accessed
the latent reservoir of the spleen before 9 dpi after
intraperitoneal inoculation.
Following intraperitoneal inoculation, cHV68 did not
require NF-jB activation for establishment of latency, or
reactivation from latency, in PECs. Since macrophages are
the major component of PECs [26], this suggests that NF-jB
activation is dispensable for establishment of cHV68 latency
in macrophages. This is consistent with the observation that
the frequency of viral genome–positive non–B cells in the
lungs at day 16 was also largely unaffected by inhibition of
NF-jB activation (see Figure 7). In contrast to PECs, there was
a slight, but signiﬁcant, decrease in latency establishment in
the spleens of mice following intraperitoneal infection with
IjBaM-cHV68. This phenotype also was apparent in a
frequency analysis of latency in sorted B-cell populations
(unpublished data). The mild phenotype upon intraperito-
neal inoculation with IjBaM-cHV68 compared to the
approximately 50-fold decrease in splenic latency upon
intranasal infection indicates that there are critical mecha-
nistic differences with respect to seeding splenic latency
between these routes of inoculation. The analysis of splenic
latency in IjBaM-cHV68–infected mice following intraper-
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cell latency that does not require an active role for the virus
in driving activation and proliferation of these infected
splenic B cells, similar to phenotypes uncovered for M2- and
v-bcl2–null viruses [44,46,51,69]. Further investigation of
splenic latency following intraperitoneal inoculation is
required to fully understand the observed differences in
establishment of splenic B-cell latency.
Requirement for NF-jB Activation in the Establishment of
Viral Latency in Lung B Cells
Following intranasal inoculation, there is a signiﬁcant
impact of inhibiting NF-jB activation on establishment of
latency in the spleen, but this phenotype is reduced
substantially upon the more direct and permissive intra-
peritoneal route of inoculation (compare Figures 4 and 7).
This raises the possibility that altered trafﬁcking of latently
infected cells to the spleen also contributes to the splenic
latency phenotype observed at day 16 with the IjBaM-
expressing virus following intranasal inoculation. Interest-
ingly, although splenic latency is established in B-cell–
deﬁcient mice after intraperitoneal inoculation, there is a
defect in the establishment of latency in the spleen following
intranasal inoculation of these mice [21,24]. Adoptive trans-
fer of B cells into B-cell–deﬁcient mice infected with cHV68
restored latency in the spleen [23]. In addition, it has
previously been reported that intranasal infection of mice
with replication defective mutants (ORF31- or ORF50-null
viruses), resulted in virus infection of B cells in the lung, yet
these viruses were not detected in the spleen [48,49]. Taken
together, the seeding of the spleen may result from
reactivation of latently infected B cells that trafﬁck from
the lungs to the spleen, thereby seeding acute virus
replication in the spleen and the subsequent establishment
of splenic latency. This led us to investigate NF-jB–mediated
functions in the lung, the site of primary infection.
As shown here, the IjBaM-expressing cHV68 was substan-
tially impaired in the establishment of latency in lung B cells
(see Figure 7), where a 90% reduction in latency in this
particular cell subset was observed. It is also notable that
increasing the inoculating dose of virus 100-fold did not
ameliorate this defect in B-cell latency in the lungs. The
defect in establishment of B-cell latency in the lungs (Figure
7), coupled with both a slight diminishment of acute
replication in the spleen (Figure 3E) and a substantial defect
in the establishment of latency in the spleen (Figure 4),
suggests that the efﬁcient seeding of cHV68 latency in the
spleen following intranasal inoculation of virus requires the
egress of latently infected B cells from the lung.
Reduction in Activated B Cells upon NF-jB Inhibition
The absence of heightened lytic replication or viral load in
latency reservoirs in mice infected with IjBaM-expressing
cHV68 demonstrates that the host is able to mount an
effective immune response (i.e., this method of targeted NF-
jB inhibition only in virus-infected cells does not appear to
result in any gross immune dysfunction). However, the
requirement of NF-jB activation for the efﬁcient establish-
ment of lung B-cell latency could reﬂect, in part, a role for
this host cell factor in mediating inﬂammatory cytokine
production by infected cells that could lead to alterations in
the recruitment, activation, and/or subsequent trafﬁcking of
infected cells to the spleen. In an examination of the proﬁle
of lymphocytes in both the lungs and spleens at early and late
times after infection, we failed to observed any signiﬁcant
differences in the numbers of B or T cells recruited to the
lungs or present in the spleens of mice infected with the
IjBaM-expressing cHV68. The number of PNA
hi and IgD
 
cells were slightly lower for IjBaM-infected mice. The
frequency of proliferating cells at 16 dpi, as detected by the
Ki67 nuclear proliferation antigen (Table 3), and conﬁrmed
by bromodeoxyuridine incorporation from 8 through 16 dpi
(unpublished data), was not dramatically reduced. This
contrasts with the nearly 3-fold decrease in the activation
of B cells in the lungs and spleens at 16 dpi as determined by
the presence of the CD69 activation marker, which correlated
with the reduction in viral load in the B cells of the lung and
spleen.
It is known that cHV68 infection results in polyclonal
activation of B cells, characterized by an upregulation of the
CD69 activation marker and an increase in nonspeciﬁc
antibody production, a process that is dependent on CD4
þ
T cells [43,70,71]. A reduction in CD69 activation has been
correlated to both a decrease in splenomegaly and splenic
latency in mice infected with cHV68 mutants deﬁcient in
vbcl-2 [69], containing a large insertion in the M3 gene [72],
or a modiﬁcation linking the ORF73 product to a CD8–T-cell
epitope [73]. The lack of an acute replication defect for the
IjBaM-expressing cHV68, as with these other mutants after
intranasal infection, substantiates the conclusion that CD69
activation correlates with differences in the levels of splenic
latency and extends that correlation to latency in B cells at
the primary site of infection. It is very unlikely that each of
these mutated ORFs has a direct role in CD69 upregulation,
as acute titers were normal for each mutant. Considering the
disconnect between the large numbers of B cells activated
and the small fraction that is virus infected, there may be a
factor secreted by latently infected B cells that activates
neighboring B cells in a paracrine manner. Nonspeciﬁc B-cell
activation might represent a mechanism by which the virus
drives B-cell participation in germinal center reactions to
increase the likelihood of gaining access to the long-lived
memory B-cell reservoir.
NF-jB activation via the classic signaling pathway drives
the expression of a multitude of proinﬂammatory molecules,
including the cytokines TNF, interleukin (IL)-1, and IL-6;
chemokines RANTES (regulated on activation, normal T-cell
expressed and secreted), macrophage inﬂammatory protein-
1a, and membrane cofactor protein-1, and the inﬂammatory
mediators inducible nitric oxide synthase and cyclooxygenase
2 (COX-2) (reviewed in [74]). These inﬂammatory molecules
are detected in lung lavage during acute cHV68 replication
[75–77] and might be altered upon infection with the IjBaM-
expressing virus. Inducible nitric oxide synthase
 /  mice have
been reported to exhibit no alteration in immune clearance
or splenomegaly upon cHV68 infection [78]. NF-jB also
drives the expression of cellular COX-2, an enzyme that
catalyzes the production of the inﬂammatory prostaglandin
E2. COX-2 is induced upon cHV68 infection in vitro, and the
inhibition of COX-2 with the nonsteroidal anti-inﬂammatory
drug NS-398 reduced viral protein production and virion
production in vitro [79]. However, this group reported that
the targeting of COX-2 did not translate into an inhibition of
acute replication in the lungs of mice upon treatment with
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infected mice and is produced upon in vitro stimulation of
lymphocytes from infected mice [80,81]. However, there was
no difference in virus growth, in establishment of latency, or
in the immune response to the virus in IL-6
 /  mice [81,82].
The inﬂammatory response to cHV68 is multifaceted,
involving the contribution of proinﬂammatory molecules
that are produced by the heterogeneous population of
infected cells and the multiple immune cell types that
inﬁltrate and are activated at the site of infection [75]. Thus,
the lack of a substantial phenotype upon the knockout of
single NF-jB–regulated inﬂammatory components is not
altogether unexpected. In future studies, the characterization
of the cytokine and chemokine responses to infection by
IjBaM-expressing cHV68 might reveal alterations of bio-
logical relevance.
Manipulation of NF-jB Activation
by Gammaherpesviruses
A number of gammaherpesvirus gene products have been
shown to modulate NF-jB activity. EBV LMP-1 and the NF-jB
modulatory proteins of KSHV, vIL-6, K15, K1, and vFLIP are
not encoded by cHV68 and, as such, are not candidates for
mediating NF-jB activation during establishment of cHV68
latency. The cHV68 viral G protein–coupled receptor (vGPCR;
encoded by ORF 74 and a homolog of the KSHV vGPCR) is a
weak inducer of NF-jB activation in a ligand-dependent
manner [83,84]. The expression of the chemokines RANTES
and macrophage inﬂammatory protein, which mediate vGPCR
activation in cell culture, are detected in the lungs of cHV68-
infected mice [85], raising the possibility that vGPCR mediated
induction of NF-jB during the acute phase of virus replication
in the lungs. However, the signiﬁcance of such modulation on
the establishment of latency is unclear, since a stop mutation in
ORF74 manifests as a defect in reactivation, not latency
establishment in vivo [83,86].
Given the importance, as shown here, of NF-jB activation
for establishment of latency in vivo, it is possible that initial
activation of NF-jB (e.g., through virus binding and entry)
may serve to promote establishment of a latent infection in
the appropriate cellular context prior to expression of
latency-associated viral genes that activate NF-jB. For
example, in the case of EBV infection of primary B cells,
NF-jB is activated upon the binding of the viral glycoprotein
gp350 to the cell surface [87]. It is not known whether binding
of the cHV68 homolog of EBV gp350, gp150, is involved in
the initial activation of NF-jB during cHV68 infection of
permissive cells. Regardless, the phenotype of the gp150-null
virus is distinct from the IjBaM phenotype [88], making it
unlikely that gp150 plays a critical role in activating NF-jB
during the establishment of viral latency. It seems very likely
that cHV68 encodes other, as-yet-unidentiﬁed, gene products
that modulate the activation of NF-jB to manipulate the cell
and the host microenvironment and thereby optimize
conditions for viral persistence.
Conclusions
We have shown here that NF-jB signaling is critical for
efﬁcient establishment of viral latency following intranasal
inoculation of cHV68 pathogenesis and, as such, likely
represents a key host factor that is manipulated by the virus
to establish latency in B cells. To our knowledge, this is the
ﬁrst report to identify a host transcription factor required for
the efﬁcient establishment of gammaherpesvirus latency in
vivo. As NF-jB signaling is intimately involved in inﬂamma-
tion and B-cell biology, future studies aim to determine the
role of speciﬁc NF-jB subunits and signaling pathways
involved in the establishment of latency, cytokine production,
trafﬁcking, proliferation, and participation of B cells in
germinal center reactions. Further characterization of the
molecular mechanisms by which cHV68 modulates NF-jB
activation is critical to understanding virus–host interactions
that transpire, ultimately allowing the virus to gain access to
the long-lived memory B-cell reservoir. We anticipate that
cHV68 latency in B cells closely parallels EBV infection in
humans, which involves virus-driven B-cell proliferation and
differentiation. In the case of EBV infection, it is thought that
the ability of the virus to manipulate B-cell differentiation
places the host at greater risk for lymphoproliferative
disorders and lymphoma. Furthermore, modulation of NF-
jB activation by EBV is clearly critical to these processes.
Exploiting cHV68 infection of mice as a model system may
lead to critical insights into the role of gammaherpesviruses
in lymphomagenesis.
Materials and Methods
Viruses and tissue culture. cHV68 WUMS (American Type Culture
Collection VR1465, http://www.atcc.org) was the WT virus. Virus
passage and titer were performed as previously described [22]. NIH
3T12 cells and MEFs were maintained in DMEM supplemented with
100 U of penicillin/ml, 100 mg of streptomycin/ml, 10% FCS, and 2
mM L-glutamate (cMEM). Cells were maintained at 37 8C in a 5% CO2
environment. MEF cells were prepared from C57BL/6 as previously
described [89]. Vero-Cre cells were a gift from David Leib and were
passaged in cMEM supplemented with 300 lg of hygromycin B/ml
(Calbiochem, http://www.calbiochem.com).
Generation of virus mutants. The cHV68 genome cloned as a BAC
was a kind gift of Ulrich Kozinowski [41]. For the generation of the
recombinant cHV68-IjBaM.1 and .2 viruses, the mutant super-
repressor form of IjBa that contains serine-to-alanine substitutions
at amino acids 32 and 36 (IjBaM) driven by the CMV immediate-early
promoter was inserted into the ORF27–ORF29b intergenic region of
cHV68. The 1.8-kb AseI-MluI fragment of pIjBaM (Stratagene, http://
www.stratagene.com) was cloned into the PmlI site (corresponding to
cHV68 genomic position 46347) of plasmid JE110 [32] that contains
the cHV68 genomic region between nucleotide positions 45237 and
48347. Insertion of the IjBaM expression construct into the PmlI site
of pJE110 in the rightward and leftward orientation generated JE110-
IjBaM.1 and JE110-IjBaM.2, respectively. To generate the targeting
construct for use in recombination, the BglII-EcoRI fragment of
pJE110-IjBaM was cloned into the suicide donor plasmid pGS284 to
generate pGS284-IjBaM. Allelic exchange with WT cHV68-BAC in
GS500 E. coli (RecA
þ) cells was performed as previously described [90],
and the insertion of IjBaM to generate recombinant cHV68-BAC-
IjBaM.1 and .2 was screened by colony PCR using primers
ACGGGCTGAAGAAGGAGCGGCTACT and TGCCCAGGTAGCCA-
TGGATAGAGG with Taq DNA polymerase (Promega, http://www.
promega.com). For generation of the marker rescue virus, the BglII-
EcoRI fragment of pJE110 was cloned into pGS284 to generate
pGS284-27-29B. Allelic exchange of this targeting plasmid with
cHV68-IjBaM.1-BAC was performed to generate cHV68-IjBaM.MR.
Loss of IjBaM was veriﬁed by diagnostic PCR as described above.
Viral stocks were generated by Superfect (Qiagen, http://www.
qiagen.com) transfection of BAC clones of cHV68-IjBaM.1 and .2 or
cHV68-IjBaM.MR into Vero-Cre cells. Following the appearance of
cytopathic effect, wells were harvested and used to infect Vero-Cre
cells to generate high-titer viral stocks.
Puriﬁcation and analysis of virion DNA. Virus was isolated from
the supernatants of infected cells when monolayers exhibited greater
than 50% cytopathic effect. After two rounds of 20-min room-
temperature spins at 2,000 3 g, clariﬁed supernatants were spun at
15,0003g for 2 h at 4 8C. The pellet was rinsed with PBS, resuspended
in 50 mM Tris (pH 7.5), 10 mM MgCl2, and 25 U of DNase (Invitrogen,
http://www.invitrogen.com), and incubated for 35 min at 37 8C before
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3g for 1 h at room temperature. The virion pellet was resuspended in
3 ml of 10 mM Tris (pH 7.5), 1 mM EDTA and mixed with 3 ml of a 23
lysis buffer containing 2% Sarkosyl, 0.5% SDS, 40 mM Tris (pH 7.5),
200 mM NaCl, 20 mM EDTA, and 333 lg/ml proteinase K (GIBCO-
BRL, http://www.gibco.com) and then incubated at 37 8C overnight.
Samples were subjected to a phenol/chloroform and chloroform
extraction, and DNA was precipitated with 3 M Na aAcetate and 2
volumes of 100% ethanol.
Southern analysis was performed with a HindIII restriction digest
of the viral DNA and a
32P-labeled probe that detects ORF27 and the
intergenic region between ORFs 27 and 29b (bp 45237 to 46420 of
cHV68 WUMS) and with a BamHI restriction digest of the viral DNA
and a
32P-labeled IjBaM probe (BamHI-XhoI fragment of pIjBaM).
Mice, infections, and organ harvests. Female C57BL/6J mice
(catalog No. 000664; The Jackson Laboratory, http://www.jax.org)
were housed at the Yerkes vivarium in accordance with federal and
university guidelines. C57BL/6-Tg(BCL2)22Wehi/J (catalog No.
002319; The Jackson Laboratory) were maintained as heterozygous
animals by breeding with C57BL6/6J mice under sterile breeding
conditions at the Yerkes vivarium. Tg(BCL2) mice contain a trans-
gene construct consisting of the human BCL2 cDNA driven by the
Emu immunoglobulin heavy chain enhancer and SV40 promoter;
BCL2 expression is thereby restricted to the B-cell lineage [60]. All
protocols for animal studies were approved by the Institutional
Animal Care and Use Committee of Emory University.
Mice between 8 and 12 wk of age were placed under isoﬂuorane
anesthesia prior to intranasal inoculation with 1,000 PFU or 1 3 10
5
PFU of virus in 20 ll of cMEM or intraperitoneal inoculation of 1,000
PFU of virus in 0.5 ml of cMEM. Spleens were harvested into cMEM,
homogenized, and ﬁltered through a 100-lm-pore nylon cell strainer
(Becton Dickinson, http://www.bd.com). Erythrocytes were removed
with red blood cell lysis buffer (Sigma, http://www.sigmaaldrich.com).
Except where indicated, pooled splenocytes from three to 15 mice
were used in all experiments. Lungs were harvested intact and brieﬂy
incubated in HEPES-buffered saline solution with 1.3 mM EDTA
supplemented with 2% fetal calf serum (HBSS
þþ) prior to inﬂation
with approximately 1 ml of 300 U/ml collagenase type I (MOP4405;
Worthington Biochemical, http://www.worthington-biochem.com)
prepared in the HBSS
þþ solution, minced, and then incubated for 1
ha t3 78C. Collagenase-disrupted lungs were homogenized, ﬁltered
through a 100-lm cell strainer, treated with blood cell lysis buffer,
and resuspended in PBS supplemented with 0.5% or 2% FCS,
depending on downstream application.
Antiviral therapy. Individual mice were weighed prior to the ﬁrst
injection and weekly thereafter. Cidofovir (Vistide; Gilead Sciences,
http://www.gilead.com) was administered subcutaneously in the scruff
of the neck at a dose of 25 mg/kg of body weight [47,48] every 3 d
between 16 and 39 dpi with 1,000 PFU of the viruses as indicated in
the legend to Figure 5.
Plaque assay. Plaque assays were performed as previously
described [53], with minor modiﬁcations. NIH 3T12 cells were plated
onto six-well pates 1 d prior to infection at 2 3 10
5 cells per well.
Organs were subjected to four rounds of mechanical disruption of 1
min each using 1.0-mm zirconia/silica beads (Biospec Products, http://
www.biospec.com) in a Mini-Beadbeater-8 (Biospec Products). Serial
10-fold dilutions of organ homogenate were plated onto NIH 3T12
monolayers in a 200-ll volume. Infections were performed for 1 h at
37 8C with rocking every 15 min. Immediately after infection, plates
were overlaid with 2% methylcellulose in cMEM. After 6 to 7 d, plates
were stained with a neutral red overlay, and plaques were scored the
next day. The limit of detection for this assay is 50 PFU per organ.
Reporter assay. NIH 3T12 cells (3 3 10
5) were seeded onto a six-
well dish 1 d prior to treatment. Cells were infected at an MOI of 1 or
10 in 200 ll for 1 h at 37 8C with rocking every 15 min and then 2 ml
of fresh medium was added. At 6 h after the addition of innoculum, a
total of 2 lg of DNA per well was transfected by the lipofection-based
method (LipofectAMINE Plus; Invitrogen). pNF-jBLuc is an NF-jB–
responsive reporter construct that expresses Photinus pyralis luciferase
(Stratagene). pMEKK expresses an activator of NF-jB (Stratagene).
pIjBaM expresses IjBa S32/36, a dominant inhibitor of NF-jB
(Stratagene), and pBSIIKS
þ (Stratagene) is an empty vector used to
bring up DNA content to equivalent levels for each transfection.
pEGFP
þ (Stratagene) was used to monitor transfection efﬁciency by
immunoﬂuorescence microscopy (Nikon, http://www.nikon.com). Cell
extracts were harvested 24 h posttransfection and assayed using the
luciferase reporter assay system (Promega). Transfections were
performed independently in triplicate at least two times.
Nuclear extract preparation and electrophoretic mobility shift
analysis. Cells were harvested, washed once in PBS, and resuspended
into ice-cold hypotonic lysis buffer (10 mM HEPES [pH 7.9], 10 mM
KCl, 1.5 mM MgCl2, 0.1 mM EDTA, 1 mM dithitothreitol, 0.5 mM
phenylmethylsulfonyl ﬂuoride, protease inhibitor cocktail; Roche,
http://www.roche.com) for 15 min prior to the addition of 1/20
volume of 10% Nonidet P-40. Nuclei were spun down, washed in
hypotonic lysis buffer, and then resuspended in high salt buffer (25%
glycerol, 20 mM HEPES [pH 7.9], 420 mM NaCl, 1.5 mM MgCl2, 0.2
mM EDTA, 0.5 mM dithitothreitol, 0.5 mM phenylmethylsulfonyl
ﬂuoride, protease inhibitor cocktail; Roche) with vigorous shaking at
4 8C. The supernatant collected after 10,0003g centrifugation for 10
min at 4 8C was nuclear extract.
Nuclear extracts were assayed for NF-jB activation by electro-
phoretic mobility shift assay. Five micrograms of nuclear extract were
incubated with a
32P-labeled oligonucleotide containing the NF-jB
consensus site, AGTTGAGGGGACTTTCCCAGGC, in a binding
reaction containing 2 mM HEPES (pH 7.9), 1 mM EDTA, 5 mM
dithiothreitol, 0.05% Triton X-100, 5% glycerol, and 2 lg of poly d(I-
C) (Roche) for 30 min at room temperature. Competition experiments
were performed with 20- and 100-fold molar excess of unlabeled
oligonucleotides containing the WT or mutated NF-jB consensus site
(AGTTGAGGCGACTTTCCCAGGC). Nucleoprotein complexes were
subjected to electrophoresis in 5% native polyacrylamide gels at 180
V, dried under vacuum, and analyzed by PhosphorImager analysis
(Typhoon 9410; Amersham Biosciences, http://www.amersham.com).
Antibodies for ﬂow cytometry. Cells resuspended in PBS supple-
mented with 2% FCS were stained for FACS using a combination of
the following antibodies: phycoerythrin (PE)- or allophycocyanin-
conjugated antibodies to CD19; ﬂuorescein isothiocyanate (FITC)-
conjugated antibodies to B220, IgD, CD69, PNA, Ki67, and the IgG1
isotype control. When necessary, rat anti-mouse CD16/CD32 (Fc
block) was used to block Fc receptors prior to staining. All reagents
were obtained from BD Biosciences (http://www.bdbiosciences.com)
except the FITC-conjugated Ki67 (Novocastra Laboratories, http://
www.ebiotrade.com/buyf/Novocastra/index.htm).
Flow cytometry. For FACS, cells were resuspended at 2310
7 cells/
ml and incubated for 30 min on ice in PBS containing 1% FCS and Fc
block. Cells were stained with PE-conjugated anti-CD19 at 5 ll per 13
10
7 cells by incubation for 30 min on ice in the dark. Cells were
washed twice with PBS containing 1% FCS and resuspended at 1 3
10
8 cells/ml. Stained cell populations were acquired using a MoFlo
ﬂuorescence activated cell sorter (DAKO, http://www.dako.com),
FACSAria (BD Biosciences), or FACSVantage (BD Biosciences).
Sorted and unsorted cell populations were resuspended in cMEM
supplemented with 10% dimethyl sulfoxide and stored at  80 8C for
limiting-dilution PCR analyses or in cMEM at 4 8C for limiting-
dilution ex vivo reactivation analyses as described below.
For ﬂow cytometry analysis, cells were resuspended at 1310
6 cells/
ml in PBS containing 2% FCS for 20 min on ice in the dark and
stained with 1:100 dilution of allophycocyanin-conjugated anti-CD19
and 1:100 to 1:200 dilution of FITC-conjugated antibodies. For
intracellular staining for the detection of the Ki67 nuclear antigen,
cells were surface stained prior to ﬁxation in 2% paraformaldehyde
and permeabilization with 0.1% Triton X-100 in PBS, followed by
incubation with 1:100 dilution of the FITC-conjugated anti-Ki67
antibody or the isotype control. Data were collected on an
FACSCaliber (BD Biosciences) and analyzed using FlowJo software
(TreeStar, http://www.treestar.com).
Magnetic cell separation. Murine B cells were isolated by depletion
of non–B cells using the B Cell Isolation Kit (Miltenyi Biotec, http://
www.miltenyibiotec.com) per the manufacturer’s recommendations.
Brieﬂy, cells were resuspended at 2 3 10
8 cells/ml in 13 PBS
containing 0.5% FCS followed by staining with Fc block (0.125 lg/
10
6 cells) on ice for 15 min. Cells were labeled with biotin-antibody
cocktail (biotin-conjugated antibodies against CD43, CD4, and Ter-
119), 10 ll per 1310
7 cells for 15 min on ice followed by staining with
anti-biotin microbeads, 20 ll per 1310
7 cells for 15 min on ice. Cells
were washed twice with PBS containing 0.5% FCS and subjected to
magnetic separation using the autoMACS (Miltenyi Biotec). Following
separation, stained cell populations were analyzed by ﬂow cytometry
as described above.
Lung B cells were isolated by positive selection of B cells using a
PE-conjugated antibody against CD19 and the PE isolation kit per the
manufacturer’s recommendations (Miltenyi Biotec). Brieﬂy, cells were
resuspended at 2 3 10
8 cells/ml in 13 PBS containing 0.5% FCS
followed by staining with Fc block (0.125 lg/10
6 cells) on ice for 15
min. Cells were labeled with CD19 conjugated to PE, 5 ll per 1310
7
cells for 30 min on ice in the dark, spun out, and resuspended in 80 ll
of PBS containing 0.5% FCS per 1 3 10
7 cells followed by staining
with anti-PE microbeads, 20 ll per 1 310
7 cells, for 15 min on ice in
the dark. Cells were washed twice with PBS containing 0.5% FCS,
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separation using the autoMACS (Miltenyi Biotec).
Limiting-dilution ex vivo reactivation analyses. Limiting-dilution
analysis to determine the frequency of cells containing virus capable
of reactivating from latency was performed as previously described
[22,26]. Brieﬂy, bulk splenocytes or sorted cell populations were
resuspended in cMEM and plated in serial 2-fold dilutions (starting
with 10
5 cells) onto MEF monolayers in 96-well tissue culture plates.
Twelve dilutions were plated per sample, and 24 wells were plated per
dilution. Wells were scored for cytopathic effect at 21 to 28 d
postplating. To detect preformed infectious virus, parallel samples of
mechanically disrupted cells were plated onto MEF monolayers. This
process kills more than 99% of live cells, which allows preformed
infectious virus to be discerned from virus reactivating from latently
infected cells [22,26]. Unless indicated otherwise, signiﬁcant levels of
preformed virus were not detected in these assays.
Limiting-dilution nested-PCR detection of cHV68 genome-positive
cells. Limiting-dilution analysis to determine the frequency of cells
harboring the viral genome was performed using a single-copy-
sensitive nested PCR assay as previously described [24,26]. Brieﬂy,
frozen samples were thawed, counted, resuspended in isotonic buffer,
a n dp l a t e di ns e r i a l3 - f o l dd i l u t i o n si nab a c k g r o u n do f1 0
4
uninfected NIH 3T12 cells in 96-well plates (Eppendorf Scientiﬁc,
http://www.eppendorf.com). Plates were covered with PCR foil
(Eppendorf Scientiﬁc), and cells were lysed with proteinase K for 6
ha t5 68C. Then, 10 ll of round 1 PCR mix was added to each well by
foil puncture. Following ﬁrst-round PCR, 10 ll of round 2 PCR mix
was added to each well by foil puncture and samples were subjected
to round 2 PCR. All cell lysis and PCR were performed on a
PrimusHT thermal cycler (MWG Biotech, http://www.mwg-biotech.
com). Products were resolved by ethidium bromide staining on 2%
agarose gels. Twelve PCRs were performed for each sample dilution,
and a total of six dilutions were performed per sample. Every PCR
plate contained control reactions (uninfected cells and ten copies,
one copy, 0.1 copy of plasmid DNA in a background of 10
4 cells). All
of the assays demonstrated approximately single-copy sensitivity with
no false positives.
Recovery of cHV68-IjBaM viruses from splenocytes. cHV68-
IjBaM.R1 and .R2 viruses were recovered from splenocytes harvested
16 dpi. Cytopathic effect was observed in wells at 14 d postplating.
Wells that exhibited viral cytopathic effect and contained the fewest
number of input splenocytes were harvested and used to infect NIH
3T12 ﬁbroblasts to generate high-titer viral stocks and viral DNA.
Statistical analyses. All data were analyzed by using GraphPad
Prism software (GraphPad Software, http://www.graphpad.com). Titer
data were statistically analyzed with the Mann-Whitney nonparamet-
ric two-tailed t-test. Based on the Poisson distribution, the frequen-
cies of reactivation and viral genome–positive cells were obtained
from the nonlinear regression ﬁt of the data where the regression line
intersected 63.2%. The frequencies of reactivation and genome-
positive cells were statistically analyzed by unpaired two-tailed t-test
of the log 63.2% effective concentration.
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